 | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
kolの履歴書 Harry Roger Büller (pulmonary embolism, embolism, pulmonary heart disease, disease, pulmonary embolism, heart, pulmonary)
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| で知られている Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL Index score: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| で知られている Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| で知られている Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL Index score: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| で知られている Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL Index score: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| で知られている Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL Index score: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| で知られている Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| で知られている Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL Index score: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| で知られている Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL Index score: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| で知られている Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL Index score: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| で知られている Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL Index score: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| で知られている Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL Index score: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| で知られている Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| で知られている Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL Index score: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| で知られている Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Harry Roger Büller：統計に影響を与えます
レポートを実行します
| Concept | World rank |
|---|---|
| scan pulmonary embolism | #1 |
| combined training gps | #1 |
| hokusaivte study | #1 |
| vka treatment treatment | #1 |
| thromboembolism treated | #1 |
| diagnostic management patients | #1 |
| dimer result | #1 |
| pioped study study | #1 |
| subsequent symptomatic cancer | #1 |
| patients artificial graft | #1 |
| abelacimab | #1 |
| uedvt recurrent vte | #1 |
| gogh dvt trial | #1 |
| patients mismatched scan | #1 |
| rnapc2 inhibition | #1 |
| combination cdrs | #1 |
| patients protein deficiencies | #1 |
| relevant major | #1 |
| consensus strategy strategy | #1 |
| annual incidence patients | #1 |
| ventilation scan chest | #1 |
| carriers thrombophilic defects | #1 |
| suspected cdr | #1 |
| p0001 saline | #1 |
| outcome recurrent | #1 |
| tb402 50 | #1 |
| chest perfusion scintigraphy | #1 |
| age multiple comorbidities | #1 |
| messages justification | #1 |
| edoxabantreated | #1 |
| 95 3633 patients | #1 |
| respondents 60 | #1 |
| presentation major | #1 |
| risk pulmonary embolism | #1 |
| nadroparin aspirin | #1 |
| rnapc2 united states | #1 |
| 9 incidence | #1 |
| normal lung scan | #1 |
| placebo rnapc2 | #1 |
| evaluable patients apixaban | #1 |
| major bleeds vka | #1 |
| scores riete score | #1 |
| warfarin cstatistic | #1 |
| severity clinical presentation | #1 |
| wellscdr | #1 |
| adjunct thrombolysis | #1 |
| 7268 patients | #1 |
| recurrent thrombosis pts | #1 |
| individualized duration | #1 |
| calfvein thrombi | #1 |
| patients ivte | #1 |
| evaluable patients 95 | #1 |
| prothrombin 20210a mutation | #1 |
| rtap lmwh | #1 |
| enoxaparin tb402 | #1 |
| idraparinux 25 | #1 |
| local radiologist experts | #1 |
| patients uedvt uesvt | #1 |
| qscan | #1 |
| absolute annual incidences | #1 |
| current comprehensions | #1 |
| individuals air travel | #1 |
| cstatistic model discrimination | #1 |
| venous thrombosis hyperglycemia | #1 |
| idraparinux | #1 |
| clinical presentation category | #1 |
| simple diagnostic strategy | #1 |
| survival lmwh | #1 |
| patients unexplained dvt | #1 |
| subcutaneous idraparinux | #1 |
| normotensive patients studies | #1 |
| risk homozygous women | #1 |
| fviii hyperhomocysteinemia | #1 |
| enoxaparin vkas | #1 |
| uesvt patients | #1 |
| gentamicin patients netilmicin | #1 |
| anticoagulants chemotherapy | #1 |
| hellp syndrome mutations | #1 |
| acenocoumarol efficacy | #1 |
| embolism randomized | #1 |
| pyridines recurrence | #1 |
| simplified geneva score | #1 |
| 5mg apixaban | #1 |
| vte procoagulant activity | #1 |
| crt cvc | #1 |
| test venography | #1 |
| heparins cancer patients | #1 |
| 208791 | #1 |
| doacs initial heparin | #1 |
| residual thrombotic mass | #1 |
| venous thromboembolism episode | #1 |
| idraparinux vte | #1 |
| principal safety | #1 |
| cdrscore combination | #1 |
| heparin vitamin antagonist | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| anticoagulants double | #1 |
| respondents lmwh | #1 |
| prediction models recurrence | #1 |
| elevated fviii patients | #1 |
| nadroparin therapeutic dose | #1 |
| hokusai‐vte trial | #1 |
| wellsrule | #1 |
| ivte clinical practice | #1 |
| cancer clinical presentation | #1 |
| 0·620·74 | #1 |
| dimer test | #1 |
| pulmonary embolism studies | #1 |
| 12 months edoxaban | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| ambulatory computers | #1 |
| org heparin | #1 |
| international thrombosis experts | #1 |
| clinical decision rule | #1 |
| probability ventilation | #1 |
| enoxaparin heparin treatment | #1 |
| unexplained dvt patients | #1 |
| bleeding clinically | #1 |
| dose daily edoxaban | #1 |
| lmwh replacement | #1 |
| treatment experimental thrombosis | #1 |
| simplified wells rule | #1 |
| combination cdrscore | #1 |
| idraparinux placebo | #1 |
| tb402 enoxaparin | #1 |
| vte location | #1 |
| intravenous unfractionated | #1 |
| patients deep | #1 |
| embolism wells | #1 |
| thromboembolism relatives | #1 |
| ivte | #1 |
| efficacy heparin therapy | #1 |
| cdr normal | #1 |
| 393 patients warfarin | #1 |
| dvt 3 | #1 |
| constans score | #1 |
| 69 conclusions | #1 |
| pulmonary angiography ultrasonography | #1 |
| protecht shr | #1 |
| warfarin cancer patients | #1 |
| animal female heparin | #1 |
| idrabiotaparinux idraparinux | #1 |
| pharmacological methods prophylaxis | #1 |
| age∗10μg | #1 |
| 3633 patients edoxabantreated | #1 |
| excluding pulmonary | #1 |
| safety clinical utility | #1 |
| thiazoles venous | #1 |
| guideline adherence justification | #1 |
| 250 patients cancer | #1 |
| anticoagulant fondaparinux | #1 |
| specificity pulmonary embolism | #1 |
| 95 elevated ctni | #1 |
| lmwh acute treatment | #1 |
| relatives mutation | #1 |
| longhaul flight | #1 |
| elderly outpatients combination | #1 |
| management study | #1 |
| severe presentation patients | #1 |
| plateletactivating antibodies risk | #1 |
| thromboembolism 3 | #1 |
| ultrasonography diagnostic | #1 |
| pulmonary embolism carriers | #1 |
| hemorrhage heparin | #1 |
| cart lower levels | #1 |
| rule exclusion | #1 |
| matisse dvt | #1 |
| apc resistance factor | #1 |
| bmi fondaparinux | #1 |
| patients khorana | #1 |
| doacs cirrhosis patients | #1 |
| uedvt terms | #1 |
| beneficial lmwh | #1 |
| extensive screening cancer | #1 |
| idraparinux recurrent thromboembolism | #1 |
| dvt anticoagulants | #1 |
| iii plg | #1 |
| rnapc2 patients | #1 |
| khorana | #1 |
| unexplained dvt | #1 |
| oral rivaroxaban treatment | #1 |
| deepvein thrombosis incidence | #1 |
| amplify trial apixaban | #1 |
| standard therapy months | #1 |
| antidote vitamin | #1 |
| baseline pvo | #1 |
| endotoxemia tests | #1 |
| failure rate efficiency | #1 |
| malignancy achieved inr | #1 |
| s1p1activation | #1 |
| aptt org | #1 |
| women factor leiden | #1 |
| pulmonary embolism tests | #1 |
| 3 idraparinux | #1 |
| cancer cdr | #1 |
| impedance thrombophlebitis | #1 |
| upper extremity uedvt | #1 |
| patients tests prevalence | #1 |
| scenarioanalysis | #1 |
| long haul flights | #1 |
| proportion 75 years | #1 |
| replacement vka | #1 |
| platelets iqr | #1 |
| fviii homocysteine | #1 |
| recurrent vte immobilization | #1 |
| 65±9years | #1 |
| efficiency subgroups | #1 |
| obstetric complications relatives | #1 |
| acute treatment lmwh | #1 |
| ddimer test patients | #1 |
| death venous thromboembolism | #1 |
| sensitivity 100 percent | #1 |
| calf dvt ultrasound | #1 |
| preferred oral anticoagulant | #1 |
| ddimer test combination | #1 |
| perfusion scan | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| ft4 level patients | #1 |
| doacs factor | #1 |
| hokusaivte trial patients | #1 |
| apixaban conventional therapy | #1 |
| standardintensity vkas doacs | #1 |
| antithrombotic prescriptions adherence | #1 |
| heparins cancer spread | #1 |
| lowmolecularweight heparin treatment | #1 |
| carriers recurrence | #1 |
| botticelli dvt dose‐ranging | #1 |
| venography feasibility | #1 |
| 560 pharmacies | #1 |
| noncarriers annual incidence | #1 |
| 25mg apixaban | #1 |
| vkas efficacy | #1 |
| pvoq | #1 |
| heparin initial treatment | #1 |
| safety idraparinux | #1 |
| leg veins patients | #1 |
| standardintensity vkas | #1 |
| lmprovement | #1 |
| compression ultrasound dvt | #1 |
| idraparinux standard therapy | #1 |
| tomography angiography vte | #1 |
| cancer 145 patients | #1 |
| efficacy outcome | #1 |
| ml1 ctpa | #1 |
| simplified rule proportion | #1 |
| withheld | #1 |
| pulmonary embolism cdr | #1 |
| sgs pretest probability | #1 |
| 5395 patients | #1 |
| monoclonal antibodies apc | #1 |
| patients compression ultrasonography | #1 |
| rnapc2 groups placebo | #1 |
| enoxaparin initial treatment | #1 |
| idraparinux versus | #1 |
| diagnostic strategies strategies | #1 |
| vte occurred | #1 |
| early time recurrence | #1 |
| puerperium diagnostic suspicion | #1 |
| 547253 | #1 |
| patients acute recurrent | #1 |
| wells rule primary | #1 |
| mdct expert radiologist | #1 |
| clinical uedvt | #1 |
| elevated biomarkers hospital | #1 |
| extra hospital visits | #1 |
| 97 compression ultrasonography | #1 |
| thrombo‐embolic events | #1 |
| avidin idrabiotaparinux | #1 |
| enoxaparin primary efficacy | #1 |
| revascularisation procedures patients | #1 |
| netherlands 5 years | #1 |
| controlled trials thrombophilia | #1 |
| clinical probability exclusion | #1 |
| combination ddimer testing | #1 |
| pulmonary angiography strategies | #1 |
| riskstroponin | #1 |
| neoplasms heparin | #1 |
| anticoagulation period | #1 |
| suspected symptomatic | #1 |
| ddimer result | #1 |
| heparin survival | #1 |
| cdrs patients | #1 |
| included patients study | #1 |
| vkas lmwh | #1 |
| intrinsic coagulation vivo | #1 |
| patients examiner | #1 |
| vka netherlands | #1 |
| 500 org | #1 |
| rivaroxaban replacement | #1 |
| incidence ctni | #1 |
| heparinoid | #1 |
| travel venous thromboembolism | #1 |
| ddimer levels cdr | #1 |
| combination nonhigh cdr | #1 |
| fxiaso enoxaparin | #1 |
| embolism suspected | #1 |
| synthetic selective factor | #1 |
| wellscdrscore | #1 |
| gastrointestinal cancer edoxaban | #1 |
| referral basis | #1 |
| ankle brachial prevalence | #1 |
| asymptomatic extension | #1 |
| bleeding rates quality | #1 |
| risk percentage points | #1 |
| elevated fviii age | #1 |
| treatment venous | #1 |
| chromogenic endotoxin | #1 |
| departments orthopedic surgery | #1 |
| excluded pulmonary | #1 |
| protein levels mortality | #1 |
| ctscanreading | #1 |
| edoxaban cancer patients | #1 |
| patients advanced malignancy | #1 |
| normal levels fviii | #1 |
| nondiagnostic lung scan | #1 |
| milliliter enoxaparin | #1 |
| preference doacs | #1 |
| heparin acenocoumarol | #1 |
| rule cdr | #1 |
| netherlands vka | #1 |
| dimer clinical | #1 |
| patients idraparinux | #1 |
| factor viii homocysteine | #1 |
| clinically suspected uedvt | #1 |
| ddimer test | #1 |
| 5‐snp scores | #1 |
| avidin placebo | #1 |
| 7268 patients suspected | #1 |
| pulmonary embolism idraparinux | #1 |
| studies 3 months | #1 |
| ldf diagnosis | #1 |
| relatives elevated levels | #1 |
| initial heparin edoxaban | #1 |
| guidelines abi | #1 |
| superficial thrombophlebitis incidence | #1 |
| venography tests | #1 |
| vitamin antagonists time | #1 |
| apixaban extended treatment | #1 |
| einstein dvt patients | #1 |
| wells clinical | #1 |
| fxainhibitors | #1 |
| vte day | #1 |
| baseline characteristics duration | #1 |
| procoagulant factors levels | #1 |
| anticoagulant treatment vte | #1 |
| elevated cardiac troponins | #1 |
| selective ddimer thresholds | #1 |
| 750 μg l1 | #1 |
| vitamin anticoagulants | #1 |
| svt lmwh | #1 |
| obese hemophilic patients | #1 |
| patients malignancy | #1 |
| ultrasonography leg veins | #1 |
| thrice daily gentamicin | #1 |
| progression svt | #1 |
| apc resistance tests | #1 |
| vte arterial | #1 |
| fetal loss miscarriage | #1 |
| topic thrombophlebitis | #1 |
| progression vte | #1 |
| study centre duration | #1 |
| death vte studies | #1 |
| low levels ft4 | #1 |
| subcutaneous length life | #1 |
| normal venogram | #1 |
| dvt 69 | #1 |
| dvt impedance plethysmography | #1 |
| venous thrombosis vwf | #1 |
| lmwh users incidence | #1 |
| vte study | #1 |
| heparins inhibition | #1 |
| lowmolecularweight heparin 95 | #1 |
| isolated deficiencies proteins | #1 |
| strategies ultrasonography | #1 |
| recurrence bleeding risk | #1 |
| treatment cumulative incidence | #1 |
| analysis hokusai | #1 |
| intravenous injections lmwh | #1 |
| heparin org 10172 | #1 |
| 3633 patients edoxaban | #1 |
| pulmonary angiography study | #1 |
| uedvt clinical | #1 |
| hokusai‐vte cancer study | #1 |
| standard treatment idraparinux | #1 |
| uesvt mortality | #1 |
| efficacy vte | #1 |
| clinical probability risk | #1 |
| ufh grade | #1 |
| followup overt cancer | #1 |
| symptomatic venous | #1 |
| 50 rivaroxaban | #1 |
| idraparinux patients | #1 |
| therapeutic doses lmwh | #1 |
| lmwh venous thrombosis | #1 |
| doacs anatomical extent | #1 |
| flebography | #1 |
| uesvt median | #1 |
| cancer patients cancer | #1 |
| venous thrombus growth | #1 |
| failure diagnostic management | #1 |
| safety outcome | #1 |
| single dose tb402 | #1 |
| patients laalleles | #1 |
| standard therapy rivaroxaban | #1 |
| false normal | #1 |
| fviii women | #1 |
| molecular weight fondaparinux | #1 |
| abnormal vaginal bleeding | #1 |
| venous thrombosis mutations | #1 |
| idraparinux 6 months | #1 |
| prophylaxis crt | #1 |
| dalteparin 6 months | #1 |
| suspected perfusion scan | #1 |
| segmental subsegmental | #1 |
| ccus 4 | #1 |
| inherited thrombophilia patients | #1 |
| ifngamma pselectin | #1 |
| crptest | #1 |
| incidence venous | #1 |
| ultrasound compression ultrasound | #1 |
| older patients cdr | #1 |
| 3 rfviia | #1 |
| symptomatic recurrent | #1 |
| doses 75 microg | #1 |
| members symptomatic carriers | #1 |
| prevalence coagulation | #1 |
| lmwhs 95 | #1 |
| graft patency patency | #1 |
| hyperhomocysteinemia relatives | #1 |
| compression ultrasonography | #1 |
| controlledstudy | #1 |
| tests pulmonary embolism | #1 |
| submassive elevated ctni | #1 |
| adjusted dose ufh | #1 |
| dose rnapc2 | #1 |
| 36 papers | #1 |
| tests venography | #1 |
| 2630 pilots | #1 |
| presenting location vte | #1 |
| patients treatment duration | #1 |
| 53 amputations | #1 |
| elderly patients dvt | #1 |
| enoxaparin vkas treatment | #1 |
| randomized studies efficacy | #1 |
| 6 months avidin | #1 |
| fibrinolysis levels | #1 |
| loss subsequent pregnancy | #1 |
| recurrent dvt dvt | #1 |
| single‐detector row | #1 |
| heparin initial | #1 |
| extended treatment edoxaban | #1 |
| protein resistance control | #1 |
| cancer patients ufh | #1 |
| thrombophlebitis tomography | #1 |
| decisions duration | #1 |
| extended anticoagulation doacs | #1 |
| category fxainhibitors | #1 |
| vka recipients | #1 |
| strategies diagnostic management | #1 |
| einsteindvt | #1 |
| lmwh rtap | #1 |
| pulmonary embolism | #1 |
| anticoagulants probability | #1 |
| fviii venous thromboembolism | #1 |
| reduceddose noacs stroke | #1 |
| smoking patency | #1 |
| patients wells rule | #1 |
| submassive incidence | #1 |
| presentation 1 week | #1 |
| 2479 relatives | #1 |
| fetal loss carriers | #1 |
| lmwhmediated | #1 |
| age recurrent vte | #1 |
| tinaquant assay comparison | #1 |
| probability lung scan | #1 |
| idraparinux vitamin antagonist | #1 |
| survival fondaparinux | #1 |
| method factor | #1 |
| cvc crt | #1 |
| cancer patients cvcs | #1 |
| lmwh plasma levels | #1 |
| venous thromboembolism idraparinux | #1 |
| pulmonary embolism life | #1 |
| normal ddimer result | #1 |
| phase doacs | #1 |
| 5 years lmwh | #1 |
| activecontrol placebo | #1 |
| mutation arg506 | #1 |
| lmwh edoxaban | #1 |
| symptomatic recurrent vte | #1 |
| coagulationinhibiting | #1 |
| crp test patients | #1 |
| 8h flight | #1 |
| ili score | #1 |
| prescriptionbased | #1 |
| d‐dimer test | #1 |
| cus strategies | #1 |
| absolute thrombotic risk | #1 |
| —brachial | #1 |
| cancer patients cdr | #1 |
| silent dvt | #1 |
| lmwh delivery | #1 |
| pvo ctscan | #1 |
| administration lmwh | #1 |
| thrombophilia late loss | #1 |
| chest perfusion scan | #1 |
| dalteparin vte treatment | #1 |
| patients initial heparin | #1 |
| intestinal microbiota coagulation | #1 |
| idraparinux months | #1 |
| relatives tafi levels | #1 |
| 123362 | #1 |
| xageneration | #1 |
| carriers relative risks | #1 |
| wells rule exclusion | #1 |
| avws prevalence | #1 |
| quantitative ddimer tests | #1 |
| uesvt uedvt | #1 |
| influenza case patients | #1 |
| ecq ankle brachial | #1 |
| combination cdr | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| cstatistic major bleeding | #1 |
| quantitative dimer | #1 |
| women elevated levels | #1 |
| fviii vte | #1 |
| rabinov | #1 |
| ctscan qscan | #1 |
| timeperiod | #1 |
| obese controls difference | #1 |
| edoxaban warfarin groups | #1 |
| diagnostic strategy primary | #1 |
| compression ultrasonography detection | #1 |
| infections gentamicin | #1 |
| alternative diagnoses patients | #1 |
| rfviia 3 | #1 |
| total vte patients | #1 |
| dose response apixaban | #1 |
| rivaroxaban dvt treatment | #1 |
| p0424 | #1 |
| laalleles platelets | #1 |
| initial treatment patients | #1 |
| diagnosis deepvein thrombosis | #1 |
| 00515 | #1 |
| daily dalteparin treatment | #1 |
| rabinovpaulin | #1 |
| clinically relevant disease | #1 |
| vka share | #1 |
| association protein levels | #1 |
| abdominal pelvic strategies | #1 |
| probability cdr | #1 |
| presenting location women | #1 |
| relative risks carriers | #1 |
| tests prevalence abi | #1 |
| bleeding einstein | #1 |
| oral apixaban treatment | #1 |
| vte risk day | #1 |
| study ecq | #1 |
| cancer edoxaban | #1 |
| vivo coagulation factor | #1 |
| heparins data | #1 |
| intracranial clinical presentation | #1 |
| embolism sensitivity | #1 |
| recurrent vte doacs | #1 |
| oral administration bsf | #1 |
| sspe proximal | #1 |
| bleeding risk lmwh | #1 |
| wells cdr | #1 |
| hokusai vte cancer | #1 |
| selective beta‐blocker treatment | #1 |
| avidin vte | #1 |
| patients normal tests | #1 |
| pulmonary embolism metaanalysis | #1 |
| inr range ttr | #1 |
| venous thrombosis recurrence | #1 |
| equinox study | #1 |
| cancer patients patients | #1 |
| cdr dimer | #1 |
| cdr ddimer levels | #1 |
| xainhibitors | #1 |
| inr studies | #1 |
| pulmonary embolism role | #1 |
| mutation relatives | #1 |
| presence venous thrombosis | #1 |
| united states rnapc2 | #1 |
| 5 avidin infusion | #1 |
| relevant bleeding | #1 |
| feasibility venography | #1 |
| matisse clinical trials | #1 |
| presenting vte location | #1 |
| cdr ddimer test | #1 |
| sustained antithrombotic effects | #1 |
| efficacy conventional treatment | #1 |
| comparison vidas assay | #1 |
| aged nadroparin | #1 |
| fetal loss stillbirth | #1 |
| reduceddose noacs warfarin | #1 |
| reduceddose noacs | #1 |
| rule dimer | #1 |
| cip diagnostic management | #1 |
| patients antithrombotic prescriptions | #1 |
| types major bleeding | #1 |
| previous surveys netherlands | #1 |
| recurrent vte statin | #1 |
| vte fatal | #1 |
| reocclusion antithrombotic drug | #1 |
| einsteinextension | #1 |
| double heterozygous carriers | #1 |
| year prophylaxis | #1 |
| 95ci tb402 | #1 |
| cancer patients uedvt | #1 |
| relatives normal fviii | #1 |
| proximal extent ipe | #1 |
| org aptt | #1 |
| edoxaban east asian | #1 |
| duration heparin treatment | #1 |
| rnapc2 groups | #1 |
| vte difference | #1 |
| quantitative ddimer testing | #1 |
| casedescription | #1 |
| compression ultrasonography patients | #1 |
| deficiency proteins | #1 |
| ufh grade 1a | #1 |
| abnormal ipg | #1 |
| pvo qscan | #1 |
| death category | #1 |
| venous thromboembolism edoxaban | #1 |
| oral edoxaban dose | #1 |
| treat thrombosis | #1 |
| coagulation fibrinolytic proteins | #1 |
| double reports | #1 |
| popliteal veins sensitivity | #1 |
| successful attenuation | #1 |
| aptt org 10172 | #1 |
| prophylaxis idraparinux | #1 |
| ldf cus | #1 |
| recurrence major bleeding | #1 |
| acute recurrent patients | #1 |
| 0·2 edoxabantreated | #1 |
| vitamin antagonist patients | #1 |
| bleeding risk treatment | #1 |
| distal clots | #1 |
| normal dimer | #1 |
| rivaroxaban lmwh vka | #1 |
| initial heparin patients | #1 |
| acquired atiii deficiency | #1 |
| questionnaires thrombosis | #1 |
| lmwh immobilization | #1 |
| local radiologist | #1 |
| tb402 12 kg1 | #1 |
| wells rules | #1 |
| postthrombotic symptoms patients | #1 |
| patients clinical probability | #1 |
| ipe expert radiologists | #1 |
| threemonth incidence | #1 |
| 20210a mutation | #1 |
| pulmonary embolism basis | #1 |
| plasma concentration fviii | #1 |
| diagnostic strategies patients | #1 |
| suspected deep | #1 |
| ventilation lung scanning | #1 |
| relatives normal levels | #1 |
| falsenormal | #1 |
| doubleheterozygotes | #1 |
| axa activity 5 | #1 |
| clinical probability patients | #1 |
| increasing levels ft4 | #1 |
| strategies abdominal pelvic | #1 |
| patients enoxaparin vkas | #1 |
| cdrscore | #1 |
| reported incidence vte | #1 |
| orthopedic thromboprophylaxis | #1 |
| women edoxaban | #1 |
| placebo 25mg apixaban | #1 |
| dvt costs | #1 |
| patients tb402 | #1 |
| hokusaivte trial | #1 |
| 15 lmwh | #1 |
| 12 kg1 enoxaparin | #1 |
| non‐invasive diagnostic work‐up | #1 |
| scores occult cancer | #1 |
| rfviia idraparinux | #1 |
| intensity vkas doacs | #1 |
| polyethylenglycolhirudin | #1 |
| ddimer test result | #1 |
| clinically suspected dvt | #1 |
| vte addition | #1 |
| qscan 3 weeks | #1 |
| weight heparinoid | #1 |
| 2 diagnostic management | #1 |
| rivaroxaban standard therapy | #1 |
| perelated death category | #1 |
| departments pharmacological prophylaxis | #1 |
| rate recurrent | #1 |
| vitamin antagonists treatment | #1 |
| fondaparinux rfviia injection | #1 |
| proximal location ipe | #1 |
| noacs prevention | #1 |
| relatives antithrombin | #1 |
| uesvt recurrent vte | #1 |
| screening carriers | #1 |
| pregnancyrelated complications relatives | #1 |
| levels procoagulant factors | #1 |
| failure cip | #1 |
| safety 60 dose | #1 |
| factual hemorrhage heparin | #1 |
| frequency venous thromboembolism | #1 |
| current practise | #1 |
| outcome clinically | #1 |
| vte risk coc | #1 |
| clinically suspected cancer | #1 |
| poc test patients | #1 |
| carriers pulmonary embolism | #1 |
| patients retropubic prostatectomy | #1 |
| studies doac treatment | #1 |
| protein mortality | #1 |
| 0·2 3633 patients | #1 |
| apixaban randomized patients | #1 |
| deep vein thrombosis | #1 |
| probability categories | #1 |
| anticoagulant treatment patients | #1 |
| probabilityscan | #1 |
| predefined outcomes vte | #1 |
| predefined outcomes | #1 |
| 50 years combination | #1 |
| timerequirement | #1 |
| subcutaneous nadroparin placebo | #1 |
| fviii normal levels | #1 |
| fviii concentration | #1 |
| oral anticoagulants phase | #1 |
| normal ddimer concentration | #1 |
| treated vka | #1 |
| lowmolecularweight heparin category | #1 |
| symptomatic legs dvt | #1 |
| amplify trial | #1 |
| variable d‐dimer thresholds | #1 |
| aged venous | #1 |
| echocardiography normotensive patients | #1 |
| laalleles | #1 |
| association travel | #1 |
| ventricular dysfunction edoxaban | #1 |
| embolism radionuclide | #1 |
| thrombosis vitamin | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| subsequent diagnosis malignancy | #1 |
| ultrasound strategies patients | #1 |
| level loss patency | #1 |
| prothrombin individuals | #1 |
| beta thromboglobulin org | #1 |
| tsh antitpo | #1 |
| acenocoumarol heparin | #1 |
| vte trial | #1 |
| elevated ctni patients | #1 |
| somittrial | #1 |
| doac recipients | #1 |
| patients reduceddose noacs | #1 |
| presentation category | #1 |
| limited screening 95 | #1 |
| coagulation clinical | #1 |
| atherosclerosis hemophilia patients | #1 |
| elevated fviii | #1 |
| outpatients symptomatic dvt | #1 |
| positive vte | #1 |
| edoxaban dalteparin | #1 |
| category perelated death | #1 |
| thrombophilia patients doacs | #1 |
| orthopedic surgery netherlands | #1 |
| time recombinant | #1 |
| patients advanced prostate | #1 |
| netherlands lmwh | #1 |
| acenocoumarol initial treatment | #1 |
| achieved inr patients | #1 |
| 95 intracranial | #1 |
| rivaroxaban acute dvt | #1 |
| exclusion pulmonary | #1 |
| major bleeding cancer | #1 |
| probability normal | #1 |
| extended anticoagulation apixaban | #1 |
| standalone ddimer testing | #1 |
| category death | #1 |
| strategy abdominal pelvic | #1 |
| proportion pulmonary embolism | #1 |
| original wells | #1 |
| recommendations dvt | #1 |
| fxainhibitors vka recipients | #1 |
| control anticardiolipin antibodies | #1 |
| prevention topic guidelines | #1 |
| lmwh departments | #1 |
| perelated death classification | #1 |
| coagulation factors markers | #1 |
| leg ultrasonography patients | #1 |
| conventional therapy enoxaparin | #1 |
| treatment idraparinux | #1 |
| factor viii relatives | #1 |
| advanced malignancy | #1 |
| ultrasonography dvt | #1 |
| matisse trials | #1 |
| undvt | #1 |
| venous thrombosis pregnancy | #1 |
| pulmonary embolism fondaparinux | #1 |
| nonhigh cdr | #1 |
| patients inherited thrombophilia | #1 |
| incidental symptomatic vte | #1 |
| dvt 56 | #1 |
| realtime bmode ultrasonography | #1 |
| early discharge strategies | #1 |
| cdr physicians | #1 |
| uesvt | #1 |
| rfviia fondaparinux | #1 |
| quantitative ddimer test | #1 |
| tb402 prevention | #1 |
| rhir lmwh | #1 |
| prospective management study | #1 |
| studies ttr | #1 |
| thrombosis vte | #1 |
| ldfr symptomatic legs | #1 |
| smoking graft patency | #1 |
| 023 relatives | #1 |
| dvt symptomatic | #1 |
| patency smokers | #1 |
| d‐dimer level | #1 |
| role exclusion | #1 |
| fondaparinux unfractionated | #1 |
| elevated levels fviii | #1 |
| heparins vitamin antagonists | #1 |
| nadroparin patients | #1 |
| heparin vitamin | #1 |
| systematic search cteph | #1 |
| vte airline pilots | #1 |
| compression ultrasonography presentation | #1 |
| prolactin venous thrombosis | #1 |
| wells simplified | #1 |
| edoxaban risk factors | #1 |
| mortality postthrombotic symptoms | #1 |
| models development studies | #1 |
| travel‐related venous thrombosis | #1 |
| initial treatment dvt | #1 |
| practiceassistants | #1 |
| symptomatic pts | #1 |
| months standard therapy | #1 |
| dalteparin major bleeding | #1 |
| 378 patients edoxaban | #1 |
| easier monitoring | #1 |
| wound haematoma | #1 |
| desogestrelcontaining coagulation factors | #1 |
| travellers thrombosis | #1 |
| statins recurrent vte | #2 |
| referred patients secondary | #2 |
| major bleeding cindexes | #2 |
| efficiency diagnostic strategies | #2 |
| uedvt cancer patients | #2 |
| months 25 | #2 |
| apixaban enoxaparin warfarin | #2 |
| clinical prediction model | #2 |
| acquired antithrombin | #2 |
| lowmolecularweight heparin women | #2 |
| vte svt | #2 |
| gauge plethysmography | #2 |
| lower clinical utility | #2 |
| common alternative diagnoses | #2 |
| concomitant thrombophilic | #2 |
| enoxaparin difference | #2 |
| simplired test | #2 |
| recombinant hirudin cgp | #2 |
| pulmonary embolism purpose | #2 |
| primary efficacy outcome | #2 |
| low‐molecular‐weight heparin | #2 |
| inflammation neutrophils thrombosis | #2 |
| uptake noacs | #2 |
| lmwh users | #2 |
| heparin administered | #2 |
| patients peripheral graft | #2 |
| annual incidences | #2 |
| clinically suspected | #2 |
| uedvt performance | #2 |
| brain metastases doacs | #2 |
| serum tnf activity | #2 |
| patients hemorr2hages | #2 |
| embolism primary | #2 |
| thromboembolism thrombophilia | #2 |
| mild risk factor | #2 |
| recurrence thromboembolism | #2 |
| mutations cleavage sites | #2 |
| venous thromboembolism enoxaparin | #2 |
| risk khorana | #2 |
| 8 wk risk | #2 |
| incidence recurrent | #2 |
| treated edoxaban | #2 |
| idraparinux vitamin | #2 |
| global public awareness | #2 |
| deficiencies proteins | #2 |
| n1423 | #2 |
| enoxaparin warfarin | #2 |
| exclusion pulmonary embolism | #2 |
| 95 0·2 | #2 |
| interleukin‐10 response | #2 |
| endogenous activated protein | #2 |
| pravastatin therapy children | #2 |
| hemorr2hages atria scores | #2 |
| ventilation scanning | #2 |
| rnapc2 doses | #2 |
| single administration tb402 | #2 |
| recurrent deep | #2 |
| hyperglycemia diagnosis | #2 |
| composite scores area | #2 |
| protein rnapc2 | #2 |
| c1173t dimorphism | #2 |
| standardised time intervals | #2 |
| prothrombin pulmonary embolism | #2 |
| symptomatic outpatients | #2 |
| euro138 | #2 |
| sspe patients patients | #2 |
| heparin treatment influenza | #2 |
| 3306 patients | #2 |
| anticoagulated patients permanent | #2 |
| vte elevated fviii | #2 |
| simplified wells | #2 |
| negative ageadjusted ddimer | #2 |
| major bleeding edoxaban | #2 |
| 17 apixaban | #2 |
| thrombophilic defects risk | #2 |
| efficiency original score | #2 |
| secondary efficiency | #2 |
| age‐adjusted d‐dimer testing | #2 |
| fibrinolysis pentoxifylline | #2 |
| current clinical challenges | #2 |
| wells cdr patients | #2 |
| cha2ds2vasc nri | #2 |
| travel venous | #2 |
| lmwh efficacy | #2 |
| major clinically | #2 |
| pulmonary embolism efficacy | #2 |
| administration rviia | #2 |
| decision rule | #2 |
| hospitalbased strategies | #2 |
| relevant patient subgroups | #2 |
| risk anticoagulation therapy | #2 |
| pharmacological strategies | #2 |
| levels coagulation factors | #2 |
| regression pravastatin | #2 |
| cdr variables cdr | #2 |
| suspected pulmonary embolism | #2 |
| computerized impedance | #2 |
| rule combined | #2 |
| alife study | #2 |
| impedance plethysmography diagnosis | #2 |
| ufh 6 months | #2 |
| influenza prothrombotic state | #2 |
| warfarintreated | #2 |
| normal ddimer test | #2 |
| dimer thresholds | #2 |
| fibrinolysis influenza | #2 |
| absolute incidence | #2 |
| ageadjusted ddimer testing | #2 |
| nct00633893 | #2 |
| pulmonary embolism asthma | #2 |
| heparin nadroparin | #2 |
| venographically | #2 |
| primary hospitalbased strategies | #2 |
| nematode anticoagulant | #2 |
| levothyroxine exposure | #2 |
| uedvt efficiency | #2 |
| fviii increased risk | #2 |
| suspected pulmonary | #2 |
| sr34006 | #2 |
| model cancer patients | #2 |
| crnm bleeds | #2 |
| 6 months scores | #2 |
| heparin effective | #2 |
| hmb primary outcome | #2 |
| embolism deep | #2 |
| safety pravastatin therapy | #2 |
| pregnancy venous thrombosis | #2 |
| oral direct inhibitors | #2 |
| score dimer | #2 |
| outcome symptomatic | #2 |
| suspected upper | #2 |
| rfviia injection rfviia | #2 |
| thyroid hormone coagulation | #2 |
| clinical probability estimate | #2 |
| tinaquant vidas | #2 |
| beta‐receptor blockade | #2 |
| computed venous | #2 |
| graft occlusion patients | #2 |
| patients oral factor | #2 |
| gcpg | #2 |
| vitamin antagonists quality | #2 |
| subsegmental emboli | #2 |
| raskob | #2 |
| secondary strategies | #2 |
| thrombophilic disorders | #2 |
| ate cancer patients | #2 |
| hokusai vte | #2 |
| major bleeding recurrent | #2 |
| treatment ttr | #2 |
| comparator individuals 95 | #2 |
| hellp syndrome prevalence | #2 |
| bleeding complications treatment | #2 |
| life treatment duration | #2 |
| ufh survival | #2 |
| hasbled score hemorr2hages | #2 |
| amadeus study | #2 |
| employees longhaul flight | #2 |
| bleeding occurred | #2 |
| rnapc2 | #2 |
| patients low probability | #2 |
| compression doppler | #2 |
| 95 dvt | #2 |
| fibrinolytic proteins | #2 |
| coumarin sensitivity | #2 |
| subcutaneous length | #2 |
| death vte | #2 |
| failure rate strategy | #2 |
| angioplasty clopidogrel | #2 |
| vitamin antagonist rivaroxaban | #2 |
| vte 12 | #2 |
| thrombosis normal | #2 |
| rivaroxaban 30 bid | #2 |
| pentasaccharide fondaparinux | #2 |
| intermediate phenotype vte | #2 |
| ddimer determination | #2 |
| vte 1000 personyears | #2 |
| presentation dvt | #2 |
| measurement ankle brachial | #2 |
| treated anticoagulants | #2 |
| venous thrombophlebitis | #2 |
| major bleeding intermediate | #2 |
| amuse strategy | #2 |
| plasmin activity inhibition | #2 |
| screening fvl | #2 |
| diagnostic lung | #2 |
| ultrasonography patients | #2 |
| n832 | #2 |
| extended constans score | #2 |
| hokusai vtecancer study | #2 |
| 95 cancer patients | #2 |
| recombinant nematode | #2 |
| limits cancer | #2 |
| years 36 | #2 |
| incidental vte | #2 |
| impedance plethysmography patients | #2 |
| recurrent vte risk | #2 |
| primary healthcare secondary | #2 |
| 95 comparator individuals | #2 |
| coagulation fibrinolytic | #2 |
| relation coagulation factors | #2 |
| surgical casts | #2 |
| khorana protecht | #2 |
| embolism safely | #2 |
| test cancer | #2 |
| blood coagulation inhibition | #2 |
| cancer addition | #2 |
| bleeding edoxaban | #2 |
| patients khorana score | #2 |
| undiagnosed malignancy | #2 |
| prolactin relation | #2 |
| antagonists vka | #2 |
| analysis venous | #2 |
| arterial thrombotic disease | #2 |
| bleeding rate patients | #2 |
| events severe | #2 |
| adapted ddimer thresholds | #2 |
| cancer recurrent vte | #2 |
| f5 r506q | #2 |
| nonpermanent heart failure | #2 |
| patients abi measurement | #2 |
| vidas assay | #2 |
| medscape | #2 |
| venous | #2 |
| apixaban lmwh vka | #2 |
| influenza coagulation | #2 |
| central localization | #2 |
| crd42017056309 | #2 |
| endotoxininduced activation coagulation | #2 |
| coagulation factors prolactin | #2 |
| quality warfarin treatment | #2 |
| incidental venous | #2 |
| fvl carriers carriers | #2 |
| mdct reference standard | #2 |
| women therapeutic doses | #2 |
| mutations propeptide | #2 |
| patients prior vte | #2 |
| clinical pretest probability | #2 |
| 20210a mutations | #2 |
| resource utilisation treatment | #2 |
| rule proportion | #2 |
| wells cdr cdr | #2 |
| performance constans rule | #2 |
| vte orthopedic surgery | #2 |
| pregnancy coc | #2 |
| sustained antithrombotic | #2 |
| ddimer assay | #2 |
| vein compressibility | #2 |
| normohomocysteinemic relatives | #2 |
| plasma d‐dimer concentration | #2 |
| biomarkers casecontrol studies | #2 |
| cdr wells cdr | #2 |
| heparin compounds | #2 |
| rivaroxaban thiazoles | #2 |
| plasma concentrations endotoxin | #2 |
| treatment deep | #2 |
| duration anticoagulant | #2 |
| risk deep | #2 |
| duration anticoagulant treatment | #2 |
| intrinsic cascade | #2 |
| efficiency strategy | #2 |
| principal safety outcome | #2 |
| blood coagulation rnapc2 | #2 |
| factor iia | #2 |
| exclude pulmonary | #2 |
| exposure flights | #2 |
| thromboinflammation cardiovascular disease | #2 |
| mutation 35 | #2 |
| 8292 patients | #2 |
| scan normal | #2 |
| received edoxaban | #2 |
| healthcare settings findings | #2 |
| thromboembolism background | #3 |
| cancer randomised trials | #3 |
| presenting location | #3 |
| crt cancer patients | #3 |
| patients ultrasonography | #3 |
| venous thromboembolism thrombophilia | #3 |
| vte major burden | #3 |
| idrabiotaparinux | #3 |
| extensive screening | #3 |
| death clinical studies | #3 |
| 20210ga | #3 |
| ultrasonography strategies | #3 |
| placebo n4 | #3 |
| incidence total vte | #3 |
| einstein studies | #3 |
| diagnosis pulmonary | #3 |
| discontinuation ufh | #3 |
| heparin heparin | #3 |
| pulmonary embolism primary | #3 |
| patients gastrointestinal cancer | #3 |
| chemotherapy prophylaxis | #3 |
| stable acute | #3 |
| bleeding 3 | #3 |
| older children vte | #3 |
| normal result | #3 |
| simplified wells specificity | #3 |
| svt vte | #3 |
| enoxaparin follow | #3 |
| tfindependent | #3 |
| monoclonal replacement | #3 |
| female hemorrhage humans | #3 |
| nct00643201 | #3 |
| subcutaneous fondaparinux | #3 |
| venous thrombosis positive | #3 |
| axa activity | #3 |
| alternative diagnoses | #3 |
| favour lmwh | #3 |
| ctnt risk stratification | #3 |
| impedance predictive | #3 |
| einstein dvt | #3 |
| low probability models | #3 |
| travel venous thrombosis | #3 |
| dvt einstein | #3 |
| bleeding major | #3 |
| wells rule gestalt | #3 |
| ventilation scan | #3 |
| lowmolecularweight heparin placebo | #3 |
| healthy donor fmt | #3 |
| cardiac troponine | #3 |
| pad smokers | #3 |
| ft4 risk | #3 |
| warfarin subgroup | #3 |
| patients venous | #3 |
| age annual incidence | #3 |
| diagnosis pulmonary embolism | #3 |
| revised geneva efficiency | #3 |
| dimer blood | #3 |
| recombinant hirudin rhir | #3 |
| coagulation influence | #3 |
| patients 6575 years | #3 |
| plethysmography impedance | #3 |
| prevalence avws | #3 |
| idrabiotaparinux warfarin | #3 |
| deep vein | #3 |
| patients incidental vte | #3 |
| einstein patients | #3 |
| protein thrombophilia | #3 |
| ddimer assays | #3 |
| outpatients dvt | #3 |
| composite stroke | #3 |
| fxiaso | #3 |
| gestalt 95 | #3 |
| dvt primary | #3 |
| adult patients vte | #3 |
| baseline values placebo | #3 |
| apc protective | #3 |
| hf severity risk | #3 |
| 3month vte incidence | #3 |
| knee factor | #3 |
| dvt major | #3 |
| thiophenes venous | #3 |
| proximalvein thrombosis | #3 |
| patients wells | #3 |
| factors prothrombin | #3 |
| cdr combination | #3 |
| topic heparin heparin | #3 |
| influence heparins | #3 |
| dip placebo | #3 |
| antithrombin iii concentrate | #3 |
| studies cus strategies | #3 |
| treatment vitamin antagonists | #3 |
| patients ft4 level | #3 |
| single diagnostic | #3 |
| mechanisms heparin | #3 |
| selectine | #3 |
| safely | #3 |
| tb‐402 | #3 |
| administration rnapc2 | #3 |
| cancer patients ate | #3 |
| dvt systematic differences | #3 |
| pulmonary embolism‐related death | #3 |
| incidence enoxaparin | #3 |
| desogestrelcontaining | #3 |
| vte low | #3 |
| inhibition blood coagulation | #3 |
| dose reduction edoxaban | #3 |
| tinaquant assay | #3 |
| outpatient treatment dvt | #3 |
| incidental pulmonary embolism | #3 |
| endogenous apc | #3 |
| strategies efficiency | #3 |
| dalteparin difference | #3 |
| cancer active cancer | #3 |
| wells rule dvt | #3 |
| thromboembolism low | #3 |
| activecontrol | #3 |
| standard therapy treatment | #3 |
| heparins cancer | #3 |
| diagnosis deep | #3 |
| pulmonary embolism gestalt | #3 |
| predictable pharmacokinetics | #3 |
| vte 3 | #3 |
| venous arterial | #3 |
| intravenous loading dose | #3 |
| introduction mdct | #3 |
| patients 6 months | #3 |
| hasbled | #3 |
| dvt hip | #3 |
| vte venous thrombosis | #3 |
| hokusai‐vte | #3 |
| female humans inhibitors | #3 |
| pph lmwh | #3 |
| detection dvt | #3 |
| oral hormonal cross | #3 |
| ipe cancer patients | #3 |
| lowmolecularweight humans length | #3 |
| primary rule | #3 |
| clinical models patients | #3 |
| primary wells rule | #3 |
| factor viiic | #3 |
| iii deficiency | #3 |
| 95 wells rule | #3 |
| multiple comorbidities polypharmacy | #3 |
| sensitivity compression | #3 |
| treatment vka | #3 |
| “gestalt | #3 |
| prevalence hemostatic abnormalities | #3 |
| time venous thrombosis | #3 |
| capillary blood sample | #3 |
| gestalt probability | #3 |
| approaches primary | #3 |
| thombosis | #3 |
| coagulation air travel | #3 |
| treatment vte recurrence | #3 |
| atria hemorr2hages | #3 |
| outcome venous | #3 |
| normal ctnt presentation | #3 |
| nadroparin placebo | #3 |
| prolactin controls | #3 |
| 3633 patients | #3 |
| safely excluded | #3 |
| venous thromboembolism apixaban | #3 |
| therapy venous | #3 |
| lmwh pph | #3 |
| patients proximalvein thrombosis | #3 |
| cancer patients ipe | #3 |
| vte performance | #3 |
| patients venography | #3 |
| failurerate | #3 |
| 12month study period | #3 |
| treatment lowmolecularweight heparin | #3 |
| recurrent thromboembolic | #3 |
| cohort study employees | #3 |
| mutation venous | #3 |
| idiopathic venous | #3 |
| rnapc2 fviia | #3 |
| definition perelated death | #3 |
| ddimer threshold | #3 |
| 6575 years | #3 |
| products follow | #3 |
| venous thrombosis cancer | #3 |
| vein thrombosis | #3 |
| probability dimer | #3 |
| safety acenocoumarol | #3 |
| lmwh | #3 |
| negative predictive proportion | #3 |
| 100 years year | #3 |
| studies hemorrhage | #3 |
| treatment low | #3 |
| venous thrombosis travel | #3 |
| thrombophilic defect | #3 |
| embolism‐related | #3 |
| 02011 | #3 |
| venous thromboembolism | #3 |
| platelet agents | #3 |
| pulmonary embolism models | #3 |
| efficacy heparin | #3 |
| users incidence | #3 |
| vte denmark | #3 |
| compensated dic | #3 |
| safely exclude | #3 |
| thrombophlebitis treatment | #3 |
| combination wells score | #3 |
| recurrence thrombophlebitis | #3 |
| 3month incidence | #3 |
| heparin edoxaban | #3 |
| subcutaneous lmwh | #3 |
| lmwhs standard heparin | #4 |
| vte highincome countries | #4 |
| lmwh female heparin | #4 |
| lmwh cancer patients | #4 |
| bleeding anticoagulants | #4 |
| vte total | #4 |
| protecht | #4 |
| received warfarin | #4 |
| treatment unfractionated heparin | #4 |
| impedance plethysmography | #4 |
| dutch orthopedic | #4 |
| leiden carriers | #4 |
| abdomen relationship | #4 |
| thromboembolism study | #4 |
| extended treatment | #4 |
| point dimer | #4 |
| patient category | #4 |
| embolism roc | #4 |
| venous thromboembolism patients | #4 |
| vte global burden | #4 |
| thromboembolism factor | #4 |
| enoxaparin day | #4 |
| 150 microg levonorgestrel | #4 |
| preexisting heparin | #4 |
| idiopathic venous thrombosis | #4 |
| contraindications treatment | #4 |
| negative point | #4 |
| ddimer assay patients | #4 |
| embolism tomography | #4 |
| 6 months prophylaxis | #4 |
| fibrin generation test | #4 |
| serial impedance | #4 |
| vka treatment | #4 |
| travel thrombosis | #4 |
| arterial thrombotic | #4 |
| coagulation endotoxin | #4 |
| diagnostic management strategies | #4 |
| patients fondaparinux | #4 |
| series venograms | #4 |
| probability prospective | #4 |
| 35±4 | #4 |
| estrogen therapy patients | #4 |
| primary failure rate | #4 |
| thromboembolism vitamin | #4 |
| thrombosis uedvt | #4 |
| edoxaban patients | #4 |
| postthrombotic symptoms | #4 |
| thrombosis deep | #4 |
| ageadjusted cutoff patients | #4 |
| hemostatic profile | #4 |
| vitamin antagonists patients | #4 |
| hyperhomocysteinemic relatives | #4 |
| patients primary healthcare | #4 |
| patients clinically | #4 |
| proximal patients | #4 |
| serial impedance plethysmography | #4 |
| rviia thrombin generation | #4 |
| vte netherlands | #4 |
| chinese korean ethnicity | #4 |
| mbe patients | #4 |
| rivaroxaban 20 | #4 |
| apixaban efficacy | #4 |
| measurement abi | #4 |
| tinaquant | #4 |
| gramnegative bacteria humans | #4 |
| cancer vwf | #4 |
| global burden vte | #4 |
| criteria dose reduction | #4 |
| prophylaxis lmwh | #4 |
| clot resolution | #4 |
| death survey | #4 |
| ultrasonography venous | #4 |
| patients crcl 60 | #4 |
| patients edoxaban | #4 |
| recurrent vte months | #4 |
| patients nonpermanent | #4 |
| 3587 | #4 |
| 150 microg desogestrel | #4 |
| thrombosis symptomatic | #4 |
| coagulation factors risk | #4 |
| questionnaires venous | #4 |
| control anticoagulation | #4 |
| refuted | #4 |
| oral rivaroxaban | #4 |
| daily netilmicin | #4 |
| risk vkas | #4 |
| diagnostic management | #4 |
| thrombosis air | #4 |
| patients alternative diagnosis | #4 |
| advanced cancer 95 | #4 |
| thromboembolism occurred | #4 |
| cleavage sites apc | #4 |
| diagnosis uedvt | #4 |
| vitamin antagonists | #4 |
| thromboembolism treatment | #4 |
| disease vte | #4 |
| women apc resistance | #4 |
| venous thrombosis levels | #4 |
| primary pulmonary embolism | #4 |
| total vte | #4 |
| chromogenic compounds | #4 |
| symptomatic deep | #4 |
| procoagulant factors | #4 |
| thrombophilic families | #4 |
| amadeus trial | #4 |
| patients dimer | #4 |
| 335 patients | #4 |
| patients venous thromboembolism | #4 |
| diagnostic prediction models | #4 |
| warfarin 3 months | #4 |
| disease burden vte | #4 |
| episode venous | #4 |
| noacs cancer patients | #4 |
| 10172 | #4 |
| thrombosis ischemic stroke | #4 |
| clinically relevant bleeding | #4 |
| chemotherapy shr | #4 |
| patient education treatment | #4 |
| nct00571649 | #4 |
| activation fibrinolytic | #4 |
| chads2 p0001 | #4 |
| rfviia injection | #4 |
| levels ft4 | #4 |
| predilution postdilution | #4 |
| vte treatment patients | #4 |
| noacs netherlands | #4 |
| vitamin antagonist treatment | #4 |
| dimer assays | #4 |
| hemorr2hages | #4 |
| “reversal | #4 |
| embolism background | #4 |
| enoxaparin female humans | #4 |
| embolism dimer | #4 |
| rule pulmonary | #4 |
| safety pravastatin | #4 |
| doac studies | #4 |
| thrombophilia 95 | #4 |
| lowmolecular weight heparins | #4 |
| vte global | #4 |
| thromboembolism arterial | #4 |
| population rivaroxaban | #4 |
| risk occult cancer | #4 |
| life duration | #4 |
| netherlands pulmonary | #4 |
| sankyo | #4 |
| 0651 | #4 |
| women normal levels | #4 |
| venography patients | #4 |
| dose noacs | #4 |
| lowmolecularweight heparin | #4 |
| clot lysis patients | #4 |
| pregnancies carriers | #4 |
| chemotherapy vte prophylaxis | #4 |
| patients submassive | #4 |
| global disease burden | #4 |
| thromboembolism systematic | #4 |
| outpatients hospital | #5 |
| women warfarin | #5 |
| vte factor | #5 |
| treatment acute dvt | #5 |
| outcome major | #5 |
| molecularweight heparin | #5 |
| burden vte | #5 |
| thrombosis upper | #5 |
| dvt prevalence | #5 |
| low molecularweight humans | #5 |
| repeated ultrasonography | #5 |
| patients parenteral anticoagulants | #5 |
| clinical probability | #5 |
| vte patients cancer | #5 |
| panwards | #5 |
| lmwh recommended | #5 |
| thromboembolism thrombosis | #5 |
| thromboembolism idraparinux | #5 |
| low‐molecular‐weight | #5 |
| medea study | #5 |
| patients wells score | #5 |
| diagnostic strategies | #5 |
| daiichi sankyo | #5 |
| day rivaroxaban | #5 |
| southern latin america | #5 |
| isolated calfvein thrombosis | #5 |
| pregnancy pph | #5 |
| risk prediction scores | #5 |
| ft4 level | #5 |
| patients pulmonary embolism | #5 |
| cdr patients | #5 |
| netilmicin patients | #5 |
| endotoxin testing | #5 |
| thrombosis leg | #5 |
| patients recurrent dvt | #5 |
| patients subtherapeutic | #5 |
| 8491 | #5 |
| bleeding cancer | #5 |
| fviii families | #5 |
| efficiency patients | #5 |
| fviia rnapc2 | #5 |
| venous thromboembolism studies | #5 |
| cancer strategy | #5 |
| adjusted dimer | #5 |
| vte 6 | #5 |
| hokusai | #5 |
| factor leiden 95 | #5 |
| secondary venous thrombosis | #5 |
| pad smoking | #5 |
| antithrombotic drug treatment | #5 |
| thromboembolism | #5 |
| inhibition plasminogen activation | #5 |
| predilution | #5 |
| severe pph women | #5 |
| secondary dvt | #5 |
| transfusion blood loss | #5 |
| patients superficial thrombophlebitis | #5 |
| coc pregnancy | #5 |
| cgp 39393 | #5 |
| preschool contraceptives | #5 |
| vka patients | #5 |
| thromboembolism studies | #5 |
| incidence prognostic significance | #5 |
| sensitivity negative predictive | #5 |
| fh patients cvd | #5 |
| lmwh incidence | #5 |
| normal ctpa | #5 |
| elevated plasma level | #5 |
| thrombosis primary | #5 |
| endogenous activated | #5 |
| deepvein thrombosis | #5 |
| embolism reproducibility | #5 |
| asymptomatic carriers mutation | #5 |
| recurrent dvt patients | #5 |
| ventricular dysfunction echocardiography | #5 |
| specificity thrombophlebitis | #5 |
| upper extremity thrombosis | #5 |
| suspected uedvt | #5 |
| rivaroxaban enoxaparin vka | #5 |
| heparin compared | #5 |
| exclusion venous thromboembolism | #5 |
| treatment fondaparinux | #5 |
| thrombophlebitis ultrasonography | #5 |
| 2 rules | #5 |
| clinical presentation clinical | #5 |
| coronary angioplasty angioplasty | #5 |
| dimer combination | #5 |
| clinical probability assessment | #5 |
| iii plasminogen | #5 |
| compression ultrasound | #5 |
| phlebography plethysmography | #5 |
| diagnosis questionnaire | #5 |
| endotoxin chimpanzees | #5 |
| consensus strategy | #5 |
| pulmonary embolism patients | #5 |
| gestalt | #5 |
| previous venous thromboembolism | #5 |
| 8292 | #5 |
| hirudin treatment | #5 |
| treatment intermittent claudication | #6 |
| arterial cardiovascular | #6 |
| daily gentamicin | #6 |
| rate major bleeding | #6 |
| enoxaparin incidence | #6 |
| cancer primary patients | #6 |
| treatment ufh | #6 |
| symptomatic legs | #6 |
| patients lowmolecularweight heparin | #6 |
| subcutaneous nadroparin | #6 |
| low absolute risk | #6 |
| perioperative blood loss | #6 |
| vte anticoagulant treatment | #6 |
| patients iohexol | #6 |
| lmwh cancer | #6 |
| dabigatran etexilate dabigatran | #6 |
| lmwh users users | #6 |
| patients suspected | #6 |
| simplired dimer | #6 |
| severe dic | #6 |
| subcutaneous low | #6 |
| neoplasms pulmonary embolism | #6 |
| initial heparin treatment | #6 |
| leiden | #6 |
| 10±4 | #6 |
| patients anticoagulation clinic | #6 |
| dimer cut | #6 |
| treatment pulmonary embolism | #6 |
| selective beta | #6 |
| treatment svt | #6 |
| d‐dimer testing | #6 |
| venograms | #6 |
| assay fibrin | #6 |
| patients factor mutation | #6 |
| probability pulmonary | #6 |
| warfarin venous thromboembolism | #6 |
| compression stockings patients | #6 |
| 049 95 | #6 |
| duration rivaroxaban | #6 |
| severe antithrombin | #6 |
| wells rule | #6 |
| factor leiden carriers | #6 |
| 39393 | #6 |
| incidence recurrence | #6 |
| standardized morbidity ratio | #6 |
| synthetic pentasaccharides | #6 |
| patients proximal | #6 |
| amplify | #6 |
| subjects vte | #6 |
| anticoagulant treatment | #6 |
| endotoxininduced activation | #6 |
| thrombosis guidelines | #6 |
| oral anticoagulants dabigatran | #6 |
| efficiency proportion | #6 |
| vka | #6 |
| women hyperhomocysteinemia | #6 |
| thromboembolism bleeding | #6 |
| 393 patients | #6 |
| levonorgestrel desogestrel | #6 |
| embolism ventricular | #6 |
| outcome occurred | #6 |
| stressinduced hyperglycaemia | #6 |
| ultrasonography normal | #6 |
| svt extension | #6 |
| conventional therapy treatment | #6 |
| patients diagnostic | #6 |
| c1173 | #6 |
| diagnostic workup | #6 |
| patients tests | #6 |
| fviia inhibition | #6 |
| fixeddose regimen | #6 |
| antagonists treatment | #6 |
| combined utility | #6 |
| dvt trial | #6 |
| pembqol questionnaire | #6 |
| vte cancer | #6 |
| patients uedvt | #6 |
| risk increasing levels | #6 |
| clinically relevant subgroups | #6 |
| endotoxin assays | #6 |
| anticoagulants hemorrhage | #6 |
| vte controls | #6 |
| risk khorana score | #6 |
| pulmonary embolism presence | #6 |
| isolated deficiencies | #6 |
| proportion cancer patients | #6 |
| dalteparin dose | #6 |
| prevalence vte | #6 |
| thrombophilic defects | #6 |
| patients pulmonary angiography | #6 |
| effects ufh | #6 |
| embolism pulmonary | #6 |
| anticoagulants female | #6 |
| repeatedly normal | #6 |
| ft4 patients | #6 |
| grade 1a ufh | #6 |
| edoxaban efficacy | #6 |
| oral edoxaban | #6 |
| myocardial infarction ctni | #6 |
| apixaban treatment dose | #6 |
| funding bayer | #6 |
| 12month cumulative incidence | #6 |
| elisapositive | #6 |
| recurrent pulmonary | #6 |
| symptoms intermittent claudication | #6 |
| effects levonorgestrel | #6 |
| blood coagulation mechanism | #6 |
| recurrent dvt | #7 |
| major bleeding vkas | #7 |
| phenprocoumon polymorphism | #7 |
| arterial cardiovascular disease | #7 |
| doppler skin | #7 |
| noncompressibility | #7 |
| combination ipg | #7 |
| aspirin combined | #7 |
| leg ultrasonography | #7 |
| diagnosis venous thrombosis | #7 |
| day initial treatment | #7 |
| primary efficacy | #7 |
| carriers venous thromboembolism | #7 |
| rates edoxaban | #7 |
| thromboembolism vte | #7 |
| 680 | #7 |
| plasma levels ifngamma | #7 |
| unselected women | #7 |
| negative ddimer test | #7 |
| embolism prospective | #7 |
| proportion older patients | #7 |
| major bleeding | #7 |
| tb402 | #7 |
| spiral sensitivity | #7 |
| general practitioners guideline | #7 |
| factor female humans | #7 |
| lung scan | #7 |
| perelated death | #7 |
| mpc1609 | #7 |
| negative predictive npv | #7 |
| prothrombin risk | #7 |
| neoplasms pulmonary | #7 |
| dvt ipg | #7 |
| mutations factor viii | #7 |
| thromboembolism total | #7 |
| heparin org | #7 |
| diagnostic suspicion | #7 |
| relation levels | #7 |
| coagulation humans | #7 |
| 220 dabigatran | #7 |
| relation prolactin levels | #7 |
| administration bsf | #7 |
| vka therapy | #7 |
| rivaroxaban 10 | #7 |
| stockings control | #7 |
| silent pulmonary embolism | #7 |
| pulmonary embolism sensitivity | #7 |
| ufh treatment | #7 |
| treatment doac | #7 |
| antithrombin protein | #7 |
| vitamin antagonists vka | #7 |
| thrombophlebitis adolescent | #7 |
| blood coagulation humans | #7 |
| specific antidotes | #7 |
| placebo rivaroxaban | #7 |
| 597939 | #7 |
| carriers defects | #7 |
| thrombophilia pregnancy loss | #7 |
| levels factor viii | #7 |
| venous thrombosis treatment | #7 |
| inhibitor apixaban | #7 |
| protein protein deficiencies | #7 |
| tnf injection | #7 |
| ottawa score | #7 |
| thromboembolism adult | #7 |
| anticoagulant parameters | #7 |
| vte cancer diagnosis | #7 |
| patients standard heparin | #7 |
| presence cteph | #7 |
| deepvein thrombosis patients | #7 |
| etexilate oral | #7 |
| major bleeding rate | #7 |
| primary dvt | #7 |
| incidence recurrent vte | #7 |
| nondiagnostic lung scans | #7 |
| statin treatment risk | #7 |
| treatment venous thrombosis | #8 |
| bnp ctnt | #8 |
| carriers fvl | #8 |
| pvoct | #8 |
| fxi aso | #8 |
| deficiency antithrombin | #8 |
| ufh initial treatment | #8 |
| inherited thrombophilic | #8 |
| severe preeclampsia patients | #8 |
| risk employees | #8 |
| contrast venography | #8 |
| years cumulative incidence | #8 |
| persistent risk factors | #8 |
| recurrent vte bleeding | #8 |
| low clinical probability | #8 |
| inr determination | #8 |
| occult cancer patients | #8 |
| p0001 hasbled score | #8 |
| comorbidity polypharmacy | #8 |
| lmwh grade 1a | #8 |
| oral glucocorticoids risk | #8 |
| discontinuation anticoagulant treatment | #8 |
| recurrent vte mb | #8 |
| euro55 | #8 |
| testing rule | #8 |
| heparin vitamin antagonists | #8 |
| chemotherapy low risk | #8 |
| overt cancer | #8 |
| 1599 patients | #8 |
| dimer tests | #8 |
| point ultrasonography | #8 |
| international organisations | #8 |
| wells scores | #8 |
| prospective management | #8 |
| patients symptomatic vte | #8 |
| increased fibrinolytic | #8 |
| v617f jak2 | #8 |
| inr values patients | #8 |
| dimer concentration | #8 |
| anticoagulants antineoplastic | #8 |
| nafronyl | #8 |
| vitamin antagonists vkas | #8 |
| aged phlebography | #8 |
| compression surveys | #8 |
| thrombosis adolescent | #8 |
| symptomatic deepvein thrombosis | #8 |
| normal computed | #8 |
| patients extended anticoagulation | #8 |
| unprovoked vte patients | #8 |
| proximal deep | #8 |
| prevention vte | #8 |
| warfarin hazard ratio | #8 |
| oac adherence | #8 |
| homocysteine markers | #8 |
| arg506 factor | #8 |
| 0·2 | #8 |
| tests pulmonary | #8 |
| enoxaparin vka | #8 |
| objectively confirmed | #8 |
| ageadjusted ddimer cutoff | #8 |
| levonorgestrelcontaining | #8 |
| 97 95 | #8 |
| analysis apixaban | #8 |
| 150 enoxaparin | #8 |
| cancer pulmonary embolism | #8 |
| consecutive outpatients | #8 |
| initial heparin | #8 |
| vka lmwh | #8 |
| patients excluded | #8 |
| products humans | #8 |
| nondiagnostic scan | #8 |
| proximal deepvein thrombosis | #8 |
| structured algorithm | #8 |
| vte score | #8 |
| vascular endothelial barrier | #8 |
| probability lung | #8 |
| leiden prothrombin | #8 |
| optimal intensity | #8 |
| xii deficient | #8 |
| agnelli | #8 |
| current approach | #8 |
| apixaban enoxaparin | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| thrombosis prophylaxis | #8 |
| duration treatment | #8 |
| oral apixaban | #8 |
| anticoagulation unprovoked vte | #8 |
| risks dvt | #8 |
| administration low | #8 |
| acute symptomatic vte | #8 |
| funding daiichi | #8 |
| physicians stockings | #8 |
| concomitant cancer | #9 |
| normal ddimer | #9 |
| cancer cell extravasation | #9 |
| apixaban oral factor | #9 |
| thrombosis thromboinflammation | #9 |
| homocysteine women | #9 |
| incidental pulmonary | #9 |
| bled bleeding | #9 |
| nonpermanent | #9 |
| diagnostic prediction model | #9 |
| strategies dimer | #9 |
| vte relatives | #9 |
| anticoagulant pathways | #9 |
| carriers factor leiden | #9 |
| postdilution | #9 |
| vte rcts | #9 |
| independent committee | #9 |
| comorbidities polypharmacy | #9 |
| treatment edoxaban | #9 |
| thrombosis compared | #9 |
| iii concentrate | #9 |
| incidence postthrombotic syndrome | #9 |
| combination stroke | #9 |
| factors thrombophlebitis | #9 |
| months efficacy | #9 |
| lmwh mortality | #9 |
| discontinuing anticoagulation | #9 |
| compression stockings prevention | #9 |
| cancer factor | #9 |
| male oligosaccharides | #9 |
| therapeutic dose patients | #9 |
| embolism venous | #9 |
| placebo plasma levels | #9 |
| patients fxa inhibitors | #9 |
| thrombosis venous thromboembolism | #9 |
| characteristics severity | #9 |
| acute medical illnesses | #9 |
| crcl 60 | #9 |
| fxa inhibitor | #9 |
| serotonin platelet | #9 |
| daiichisankyo | #9 |
| thromboembolism cancer | #9 |
| tafi levels | #9 |
| edoxaban major bleeding | #9 |
| generation pill | #9 |
| method enoxaparin | #9 |
| enoxaparin factor | #9 |
| heparin therapy patients | #9 |
| oral contraceptive pregnancy | #9 |
| major bleeding treatment | #9 |
| abnormal vaginal | #9 |
| patients active cancer | #9 |
| treatment prophylaxis | #9 |
| hemorr2hages atria | #9 |
| longterm treatment vte | #9 |
| büller | #9 |
| ultrasonogram | #9 |
| weight heparin | #9 |
| oral antithrombins | #9 |
| prothrombin 20210a | #9 |
| atiii concentrates | #9 |
| diagnosis mdct | #9 |
| cancer episode | #9 |
| cofact | #9 |
| lipoproteina women | #9 |
| fondaparinux cancer patients | #9 |
| oral administration dabigatran | #10 |
| embolism patients | #10 |
| inr cases | #10 |
| normohomocysteinemic | #10 |
| single loss | #10 |
| fii mutation | #10 |
| subcutaneous metaanalysis | #10 |
| thrombophlebitis adult | #10 |
| major bleeding crnmb | #10 |
| vnv | #10 |
| factor prevention | #10 |
| crp test | #10 |
| bled scores | #10 |
| 100 years discontinuation | #10 |
| magellan study | #10 |
| cancer patients vte | #10 |
| extremity deep | #10 |
| gramnegative septicemia | #10 |
| treatment vitamin | #10 |
| leg veins | #10 |
| hypocoagulable state | #10 |
| year years | #10 |
| lmwh studies | #10 |
| dvt lower extremity | #10 |
| intimamedia thickness imt | #10 |
| factor levels patients | #10 |
| treatment aprotinin | #10 |
| asymptomatic pulmonary embolism | #10 |
| 1215 patients | #10 |
| wells | #10 |
| thr incidence | #10 |
| patients venous thrombosis | #10 |
| anticoagulants | #10 |
| cus diagnosis | #10 |
| retrospective study efficacy | #10 |
| thrombosis background | #10 |
| injection avidin | #10 |
| venous thrombosis | #10 |
| schedule heparin | #10 |
| pregnancy carriers | #10 |
| embolism clinical | #10 |
| protein dic | #10 |
| simplified geneva | #10 |
| magellan trial | #10 |
| animal heparin | #10 |
| inherited thrombophilic factors | #10 |
| incidence 1000 personyears | #10 |
| rabbits administration | #10 |
| probability pulmonary embolism | #10 |
| ageadjusted cutoff | #10 |
| rfviia blood loss | #10 |
| ddimer concentration | #10 |
| patients endotoxemia | #10 |
| 598 patients | #10 |
| rates recurrent vte | #10 |
| deficiencies antithrombin | #10 |
| oral thrombin inhibitor | #10 |
| venous thromboembolic event | #10 |
| cancer patients lmwh | #10 |
| aged antithrombin | #10 |
| vte efficacy | #10 |
| treatment uedvt | #10 |
| heparin nomogram | #10 |
| snp scores | #10 |
| severity clinical | #10 |
| induced coagulation | #10 |
| 4470 | #10 |
| cvd fh patients | #10 |
| incidence major bleeding | #10 |
| fondaparinux risk | #10 |
| nadroparine | #10 |
| d‐dimer levels | #11 |
| weight humans | #11 |
| endotoxin pentoxifylline | #11 |
| pulmonary angiography venography | #11 |
| medical conferences | #11 |
| clinical pretest | #11 |
| patients probability | #11 |
| hospital lmwh | #11 |
| 30 microg ethinylestradiol | #11 |
| pyridines thiazoles | #11 |
| edoxaban | #11 |
| pcc dabigatran | #11 |
| levels prolactin | #11 |
| org 10172 | #11 |
| patients cvcs | #11 |
| embolism recurrence | #11 |
| fondaparinux hemorrhage | #11 |
| 880 patients | #11 |
| sulfates dermatan | #11 |
| lmwh pregnancy | #11 |
| knee clinical trials | #11 |
| factor venous | #11 |
| lmwh pregnancies | #11 |
| intensity anticoagulation | #11 |
| cancer patients evidence | #11 |
| thromboembolism major | #11 |
| inhibitors hemorrhage | #11 |
| pulmonary embolism incidence | #11 |
| carriers factor | #11 |
| dvt | #11 |
| recombinant human tnf | #11 |
| patients anticoagulant treatment | #11 |
| endotoxin assay | #11 |
| vte vwf | #11 |
| screening cancer | #11 |
| incidence major | #11 |
| pregnancyrelated complications | #11 |
| variation inr | #11 |
| 750 μg | #11 |
| cancer patients dvt | #11 |
| air travel | #11 |
| crnmb 95 | #11 |
| previous venous | #11 |
| mutations prevalence | #11 |
| combination dimer | #11 |
| gentamicin treatment patients | #11 |
| reference testing | #11 |
| dabigatran enoxaparin | #11 |
| embolism prevalence | #11 |
| ldfr | #11 |
| patients cancer vte | #11 |
| adult anticoagulants | #11 |
| oral dabigatran | #11 |
| haemophilia vwd | #11 |
| heparinoid org | #11 |
| ufh studies | #11 |
| gps training | #11 |
| warfarin therapy inr | #12 |
| thrombophilic | #12 |
| patients incidental | #12 |
| treatment crt | #12 |
| annual incidence vte | #12 |
| 72 children | #12 |
| stopping anticoagulation | #12 |
| warfarin recurrent vte | #12 |
| peghirudin | #12 |
| anticoagulation unprovoked | #12 |
| ageadjusted ddimer | #12 |
| bayer schering pharma | #12 |
| proximal vein | #12 |
| deficient women | #12 |
| outpatient management patients | #12 |
| prevention venous thrombosis | #12 |
| noacs vka | #12 |
| crd42013003526 | #12 |
| thrombin generation fibrinolysis | #12 |
| control metaanalysis | #12 |
| recurrent vte anticoagulation | #12 |
| dvt treatment | #12 |
| outcomes venous thromboembolism | #12 |
| vka noacs | #12 |
| thrombosis dvt | #12 |
| fondaparinux unfractionated heparin | #12 |
| subsegmental pulmonary emboli | #12 |
| months primary | #12 |
| patients lmwhs | #12 |
| anticoagulant factor | #12 |
| concomitant disorders | #12 |
| paulin | #12 |
| vte recurrence risk | #12 |
| geneva score | #12 |
| proximal veins | #12 |
| topic venous | #12 |
| safety efficiency | #12 |
| factor leiden prothrombin | #12 |
| doseadjustment | #12 |
| observation risk | #12 |
| hirulog1 | #12 |
| venous thromboembolism incidence | #12 |
| warfarin treated | #12 |
| 9702 | #12 |
| risk venous | #12 |
| livebirth rate | #12 |
| event recurrence | #12 |
| pioped study | #12 |
| female heparin humans | #12 |
| nephro | #12 |
| bnp cardiac troponin | #12 |
| perelated | #12 |
| hemodynamically stable | #12 |
| humanized arthroplasty | #12 |
| women factor | #12 |
| 9295 | #12 |
| recurrent vte | #12 |
| patients lupus anticoagulant | #12 |
| bayer healthcare | #13 |
| inhibition tnf | #13 |
| pselectin patients | #13 |
| continuous intravenous heparin | #13 |
| vte groups | #13 |
| major hip | #13 |
| hematologic pregnancy trimester | #13 |
| dimer testing | #13 |
| clinical decision rules | #13 |
| category studies | #13 |
| groups inr | #13 |
| safety oral | #13 |
| superficial thrombophlebitis | #13 |
| nct00986154 | #13 |
| safety doacs | #13 |
| concomitant antiplatelet therapy | #13 |
| vte recurrence 95 | #13 |
| deepvein thrombosis dvt | #13 |
| marder score | #13 |
| recombinant hirudin rhirudin | #13 |
| association venous thrombosis | #13 |
| arterial thromboembolism ate | #13 |
| heparin low | #13 |
| dabigatran vte | #13 |
| 95 carriers | #13 |
| patients anticoagulant | #13 |
| spiral computed tomography | #13 |
| plethysmograms | #13 |
| factor leiden mutation | #13 |
| vte major | #13 |
| rivaroxaban thiophenes | #13 |
| bleeding events edoxaban | #13 |
| randomized cross | #13 |
| thrombosis young | #13 |
| arixtra | #13 |
| inferiority efficacy | #13 |
| vte female humans | #13 |
| treatment venous thromboembolism | #13 |
| thrombosis acute | #13 |
| vte 64 | #13 |
| indication anticoagulation | #13 |
| occult cancer | #13 |
| factor viii apc | #13 |
| daily subcutaneous | #13 |
| 86 percent | #13 |
| plethysmography | #13 |
| antithrombin iii activity | #13 |
| prevention venous thromboembolism | #13 |
| patients thrombophilia | #13 |
| time prothrombin | #13 |
| conventional anticoagulants | #13 |
| strain gauge plethysmography | #13 |
| selective testing | #13 |
| levels factor | #13 |
| ufh dalteparin | #13 |
| dimer threshold | #13 |
| uedvt | #13 |
| obesity haemophilia patients | #13 |
| dvt lower | #13 |
| vte | #13 |
| dabigatran 220 | #13 |
| symptomatic pulmonary | #14 |
| patients acute vte | #14 |
| placebo rfviia | #14 |
| effects hyperthyroidism | #14 |
| dvt lower extremities | #14 |
| edoxaban warfarin | #14 |
| crnm | #14 |
| treated lmwh | #14 |
| factor viii levels | #14 |
| 17 placebo | #14 |
| awareness pad | #14 |
| pregnancy venous | #14 |
| recurrent venous thromboembolism | #14 |
| bolus intravenous injection | #14 |
| anticoagulant rivaroxaban | #14 |
| patients vka therapy | #14 |
| atiii deficiency | #14 |
| thromboembolism age | #14 |
| patients outpatients | #14 |
| conventionaltherapy | #14 |
| costs dvt | #14 |
| doseranging study | #14 |
| recurrent venous | #14 |
| experimental endotoxaemia | #14 |
| female fibrin | #14 |
| incidence severe pph | #14 |
| aged anticoagulants | #14 |
| vte months | #14 |
| limited screening | #14 |
| higher ddimer levels | #14 |
| vte statin | #14 |
| revised geneva | #14 |
| unprovoked vte vte | #14 |
| 12 kg1 | #14 |
| cadherins endothelium | #14 |
| fvl carriers | #14 |
| aged plethysmography | #14 |
| treatment duration patients | #14 |
| ultrasound strategies | #14 |
| patients dvt | #14 |
| standard heparin | #14 |
| low molecular | #14 |
| cancer patients anticoagulation | #14 |
| thrombosis | #14 |
| edoxaban oral factor | #14 |
| gastrointestinal bleeding patients | #14 |
| safety edoxaban | #14 |
| acute deep | #14 |
| obstetric complications women | #14 |
| lmwh vka | #14 |
| plasminogen apoa | #14 |
| aspirin women | #14 |
| thrombophilia patients | #14 |
| loss women | #14 |
| riete score | #14 |
| lomoparan | #15 |
| experimental thrombosis | #15 |
| thrombinography | #15 |
| diagnosis venous | #15 |
| antagonist vka | #15 |
| symptomatic events | #15 |
| recombinant factor viia | #15 |
| control subjects prevalence | #15 |
| edoxaban treatment | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| anticoagulants patients | #15 |
| pregnancy outcome pregnancy | #15 |
| generation oral | #15 |
| 500 pg | #15 |
| inr range | #15 |
| arg562 | #15 |
| vitaminkantagonists | #15 |
| treatment 12 months | #15 |
| thrombosis diagnosis | #15 |
| coc vte | #15 |
| prophylaxis venous thromboembolism | #15 |
| prior venous thromboembolism | #15 |
| cardiovascular diseases thrombosis | #15 |
| activation contact | #15 |
| patients ctpa | #15 |
| doacs aspirin | #15 |
| enoxaparin vte | #15 |
| arg506 | #15 |
| probability assessment | #15 |
| inr patient | #15 |
| established vte | #15 |
| oral direct factor | #15 |
| lmwh ufh | #15 |
| factor leiden | #15 |
| thrombus growth | #15 |
| subcutaneous enoxaparin | #15 |
| clinically relevant endpoints | #15 |
| khorana score | #15 |
| fondaparinux efficacy | #15 |
| subcutaneous regimen | #15 |
| thyroid hormone excess | #15 |
| coagulation | #15 |
| studies pulmonary | #15 |
| abdominal pelvic | #15 |
| cteph incidence | #15 |
| primary safety outcome | #15 |
| patients vitamin antagonists | #15 |
| thrombosis haemostasis | #16 |
| recurrent symptomatic | #16 |
| avws patients | #16 |
| thromboembolism time | #16 |
| major bleeding events | #16 |
| analysis rivaroxaban | #16 |
| subsequent pregnancy loss | #16 |
| risk clinically | #16 |
| test clinical | #16 |
| netilmicin gentamicin | #16 |
| ddimer levels patients | #16 |
| cancer screening patients | #16 |
| abdomino | #16 |
| factors major | #16 |
| warfarin acenocoumarol | #16 |
| positivity threshold | #16 |
| combination clinical | #16 |
| major bleeding anticoagulation | #16 |
| impaired fibrinolysis | #16 |
| women unexplained | #16 |
| vterelated death | #16 |
| 6 months placebo | #16 |
| thrombosis adult | #16 |
| postthrombotic syndrome children | #16 |
| venous thrombosis warfarin | #16 |
| cancer cancer patients | #16 |
| factor inhibitor | #16 |
| thrombosis low | #16 |
| dvt lmwh | #16 |
| vte khorana score | #16 |
| arterial vascular events | #16 |
| bleeding aged | #16 |
| thrombosis association | #16 |
| occult cancer detection | #16 |
| deep venous thrombosis | #16 |
| 100 95 | #16 |
| viia activity | #16 |
| patients acenocoumarol | #16 |
| ctscans | #17 |
| excessive blood loss | #17 |
| permanent patients | #17 |
| dvt prevention | #17 |
| vkorc1 gene | #17 |
| lower specificity | #17 |
| 12 months patients | #17 |
| management crt | #17 |
| mutation women | #17 |
| recurrent vte events | #17 |
| patients impedance | #17 |
| 516 patients | #17 |
| factor monoclonal | #17 |
| topic hemorrhage humans | #17 |
| fragment f1 | #17 |
| 2688 | #17 |
| vte edoxaban | #17 |
| anticoagulant therapy patients | #17 |
| scan classification | #17 |
| female humans vte | #17 |
| dimer assay | #17 |
| factors venous | #17 |
| incidence pts | #17 |
| prohemostatic | #17 |
| thromboembolism patients | #17 |
| anticoagulants drug | #17 |
| anticoagulants clinical | #17 |
| rivaroxaban oral factor | #17 |
| thrombosis clinical | #17 |
| women mutation | #17 |
| endotoxemia bacteremia | #17 |
| diagnosis svt | #17 |
| pharmo record linkage | #17 |
| fibrinolysis treatment | #17 |
| lmwhs patients | #17 |
| patients overt hypothyroidism | #17 |
| compared enoxaparin | #17 |
| gentamicin netilmicin | #17 |
| hematoma heparin | #17 |
| hivinfected patients cart | #18 |
| edoxaban vte | #18 |
| women pregnancy loss | #18 |
| weight adjusted | #18 |
| annual incidence | #18 |
| prothrombin g20210a | #18 |
| poc test | #18 |
| sanofi aventis | #18 |
| treatment vkas | #18 |
| diagnostic strategy | #18 |
| simplired | #18 |
| outcome events | #18 |
| vka vte | #18 |
| antithrombotic treatment patients | #18 |
| lmwh doacs | #18 |
| proximal vein thrombosis | #18 |
| flight hours | #18 |
| 4 clinical | #18 |
| thrombosis total | #18 |
| patients strategy | #18 |
| stable anticoagulation | #18 |
| 023 | #18 |
| intravenous heparin therapy | #18 |
| thrombosis pulmonary | #18 |
| venous thromboembolism rivaroxaban | #18 |
| favor lmwh | #18 |
| cancer vte | #18 |
| commercial airline pilots | #18 |
| aptt heparin | #18 |
| warfarin hazard | #18 |
| apc thrombin generation | #18 |
| vka edoxaban | #18 |
| thromboembolism venous | #18 |
| relevant nonmajor | #18 |
| combined form | #18 |
| vwf vte | #19 |
| dvt rivaroxaban | #19 |
| fondaparinux enoxaparin | #19 |
| treatment heparin | #19 |
| low platelets | #19 |
| systemic activation coagulation | #19 |
| 56 95 | #19 |
| recurrence vte | #19 |
| coagulation studies | #19 |
| patients prevalence | #19 |
| doubleblinding | #19 |
| venous thromboembolism relatives | #19 |
| fibrinolytic response | #19 |
| recurrent venous thrombosis | #19 |
| ufh lmwh | #19 |
| edoxaban dose | #19 |
| local angiogenesis | #19 |
| thromboembolism administration | #19 |
| endogenous fibrinolysis | #19 |
| 35 women | #19 |
| versions version | #19 |
| active search | #19 |
| adjusted dose | #19 |
| studies factor | #19 |
| retropubic prostatectomy | #19 |
| ipdma | #19 |
| ddimer tests | #19 |
| venography sensitivity | #19 |
| objective testing | #19 |
| patients major bleeding | #19 |
| antibodynegative | #19 |
| extended oral | #19 |
| acute recurrent | #19 |
| lmwh patients | #19 |
| patients elevated biomarkers | #19 |
| patients sspe | #19 |
| vitamin antagonist | #19 |
| increased risk relatives | #19 |
| prognostic echocardiography | #19 |
| patients derivation | #19 |
| symptomatic dvt | #19 |
| subcutaneous dalteparin | #19 |
| abnormal ultrasound | #19 |
| oral dabigatran enoxaparin | #19 |
| increased fibrinolytic activity | #19 |
| carriers prothrombin | #20 |
| life venous thrombosis | #20 |
| therapy rivaroxaban | #20 |
| thrombosis ultrasonography | #20 |
| incidences death | #20 |
| anticoagulation clinic | #20 |
| dabigatran 150 | #20 |
| recurrence bleeding | #20 |
| ctnt bnp | #20 |
| residual venous | #20 |
| excluded patients | #20 |
| shr 95 | #20 |
| patients ddimer testing | #20 |
| warfarin edoxaban | #20 |
| intravenous injections | #20 |
| proteins thrombin | #20 |
| treatment vte | #20 |
| abi risk factors | #20 |
| blindly | #20 |
| statin vte | #20 |
| guidance ssc | #20 |
| nadroparin | #20 |
| absolute risk | #20 |
| single criterion | #20 |
| cancer severity | #20 |
| calf veins | #20 |
| risk thrombophilia | #20 |
| synthetic cross | #20 |
| standardtherapy hazard ratio | #20 |
| subsegmental | #20 |
| diagnostic workup patients | #20 |
| impedance plethysmography ipg | #20 |
| thrombophilia vte | #20 |
| new agent | #20 |
| versions questionnaire | #20 |
| compared ufh | #20 |
| antagonists vkas | #20 |
| antitpo | #20 |
| malignancy time | #20 |
| abi measurement | #20 |
| symptomatic venous thrombosis | #20 |
| prothrombin mutation | #20 |
| established atherosclerosis | #20 |
| injections subcutaneous | #20 |
| portola | #20 |
| distance treatment | #20 |
| control situation | #20 |
| pregnancyrelated vte | #20 |
| hemostatic abnormalities | #21 |
| current standard treatment | #21 |
| patients 3 months | #21 |
| distance quality | #21 |
| internists cardiologists | #21 |
| hemodynamically stable patients | #21 |
| thromb | #21 |
| deep venous | #21 |
| concomitant anti | #21 |
| thrombosis anticoagulants | #21 |
| disease ischemic | #21 |
| carriers noncarriers | #21 |
| outcome incidence | #21 |
| ddimer concentrations | #21 |
| treatment apixaban | #21 |
| fibrinolysis inflammation | #21 |
| venogram | #21 |
| occult malignancy | #21 |
| treatment acenocoumarol | #21 |
| doacs lmwhs | #21 |
| prothrombin 20210 | #21 |
| d‐dimer | #21 |
| risk cohort study | #21 |
| major bleeding patients | #21 |
| vte patients | #21 |
| discriminatory performance | #21 |
| host defense response | #22 |
| dose subcutaneous | #22 |
| thrombophilia screening | #22 |
| cttr | #22 |
| patients recurrent symptoms | #22 |
| safety treatment | #22 |
| acute vte | #22 |
| public awareness | #22 |
| patients immobilization | #22 |
| cmax ctrough | #22 |
| patients severe hf | #22 |
| anticoagulants humans | #22 |
| hormonal cross | #22 |
| recurrent thromboembolism | #22 |
| riskbenefit ratio | #22 |
| treatment dvt | #22 |
| vascular endotoxins | #22 |
| venous thromboembolic | #22 |
| dichotomously | #22 |
| doppler venous thrombosis | #22 |
| bleeding treatment | #22 |
| anticoagulants heparin | #22 |
| dimer age | #22 |
| ttr inr | #22 |
| patientyears | #22 |
| daily enoxaparin | #22 |
| alternative anticoagulation | #22 |
| lpa plasminogen | #22 |
| time inr | #22 |
| odis | #23 |
| clotbound thrombin | #23 |
| thromboembolism anticoagulants | #23 |
| 011 | #23 |
| enoxaparin 40 | #23 |
| recurrence venous | #23 |
| standardduration | #23 |
| n1157 | #23 |
| lower extremity amputation | #23 |
| normal angiogram | #23 |
| prevalence venous thromboembolism | #23 |
| percentage increase | #23 |
| kakkar | #23 |
| vte studies | #23 |
| fondaparinux | #23 |
| hasbled score | #23 |
| patients coagulation disorders | #23 |
| time platelet | #23 |
| venous arterial thrombosis | #23 |
| bidirectional relation | #23 |
| life pulmonary embolism | #23 |
| rivaroxaban dosing | #23 |
| gentamicin patients | #23 |
| 5392 | #23 |
| 2 investigators | #23 |
| cancer patients risk | #23 |
| development dic | #23 |
| elevated ctni | #23 |
| ambulatory cancer patients | #23 |
| direct factor inhibitors | #23 |
| independent external validation | #24 |
| predefined criteria | #24 |
| levels fviii | #24 |
| food drugs | #24 |
| safety fondaparinux | #24 |
| fondaparinux placebo | #24 |
| a21gly | #24 |
| patients severe bleeding | #24 |
| followup incidence | #24 |
| subtherapeutic | #24 |
| desogestrel levonorgestrel | #24 |
| thrombosis carriers | #24 |
| parameters fibrinolysis | #24 |
| ddimer testing | #24 |
| therapy heparin | #24 |
| rates venous thromboembolism | #24 |
| 049 | #24 |
| patients abnormal perfusion | #24 |
| prevalence deficiencies | #24 |
| viiic | #24 |
| patients acute treatment | #24 |
| month incidence | #24 |
| recurrent thromboembolism patients | #24 |
| overt hyperthyroidism | #24 |
| lowmolecularweight humans | #24 |
| recurrent pulmonary embolism | #24 |
| years episode | #24 |
| bleeding complication | #24 |
| ufh patients | #24 |
| specific antidote | #24 |
| presence dvt | #24 |
| factors anticoagulants | #25 |
| expert radiologists | #25 |
| cha2ds2vasc chads2 | #25 |
| sepsis intravascular coagulation | #25 |
| willebrand factor adamts13 | #25 |
| perfusion lung scan | #25 |
| lmwh treatment | #25 |
| middeldorp | #25 |
| treatment symptomatic | #25 |
| fibrinogen degradation | #25 |
| thromboembolism acute | #25 |
| specificity efficiency | #25 |
| influence smoking | #25 |
| f1 2 levels | #25 |
| vte clinical | #25 |
| patients gastrointestinal bleeding | #25 |
| xii activity | #25 |
| fatima | #25 |
| amadeus | #25 |
| studies lmwh | #25 |
| anatomical extent | #25 |
| suggestions improvement | #25 |
| rate recurrent vte | #26 |
| parameters risk | #26 |
| specificity negative predictive | #26 |
| unprovoked vte | #26 |
| treatment lmwh | #26 |
| edoxaban versus | #26 |
| rethoracotomy | #26 |
| dalteparin ufh | #26 |
| patients symptomatic dvt | #26 |
| hormonal manipulation | #26 |
| ecq | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| patients essential thrombocythaemia | #26 |
| patients cdr | #26 |
| edoxaban vka | #26 |
| events year | #26 |
| doacs vitamin antagonists | #26 |
| major bleeding bleeding | #26 |
| venous thromboemboli | #26 |
| 9715 | #26 |
| viia complex | #26 |
| miscarriage stillbirth | #26 |
| failure rate | #26 |
| homozygous carriers | #26 |
| asymptomatic carriers | #26 |
| nonmajor | #27 |
| combined training | #27 |
| venous thromboembolism carriers | #27 |
| 0·63 | #27 |
| patients elevated levels | #27 |
| low molecularweight heparin | #27 |
| patients major hemorrhage | #27 |
| anticoagulants factor | #27 |
| vte thr | #27 |
| lowmolecularweight heparin patients | #27 |
| unprovoked venous | #27 |
| current guidance | #27 |
| lmwh prophylaxis | #27 |
| extremity venous | #27 |
| training gps | #27 |
| thrombosis venous | #27 |
| vte doacs | #27 |
| npv patients | #27 |
| thrombophlebitis | #27 |
| perfusion lung | #27 |
| treating physician | #27 |
| enoxaparin female | #27 |
| day 35 | #27 |
| noncarriers 95 | #27 |
| airline pilots | #27 |
| anticoagulants blood | #27 |
| patients 50 | #27 |
| female heterozygote | #27 |
| months studies | #27 |
| thrombocytopenia antibodies | #27 |
| cancer spread | #27 |
| unexplained | #28 |
| 4650 | #28 |
| embolism retrospective | #28 |
| pembqol | #28 |
| patients unprovoked | #28 |
| vitamin aged | #28 |
| tests diagnostic | #28 |
| pph severe pph | #28 |
| presentation followup | #28 |
| receiving rivaroxaban | #28 |
| vte 6 months | #28 |
| acutely medical patients | #28 |
| anticoagulants compared | #28 |
| cancer venous thromboembolism | #28 |
| rfviia placebo | #28 |
| coagulation tissue factor | #28 |
| therapeutic doses | #28 |
| 2½ | #28 |
| objective tests | #28 |
| specific reversal agent | #28 |
| anticoagulation women | #28 |
| apc plasma | #28 |
| hirudin therapy | #28 |
| factors recurrent | #28 |
| monitoring therapy | #28 |
| oral glucocorticoids | #29 |
| thrombosis 95 | #29 |
| years year | #29 |
| pbac score | #29 |
| patients standard therapy | #29 |
| direct oral anticoagulants | #29 |
| thrombo | #29 |
| thrombosis treatment | #29 |
| pulmonary embolism death | #29 |
| patients avws | #29 |
| dvt pulmonary embolism | #29 |
| spread cancer | #29 |
| sex‐specific differences | #29 |
| major bleeding rivaroxaban | #29 |
| g20210a mutation | #29 |
| resistance activated protein | #29 |
| 8240 | #29 |
| plateletactivating antibodies | #29 |
| current management strategies | #29 |
| aged morpholines | #29 |
| diagnosis dvt | #29 |
| prediction scores | #29 |
| dutch famine | #29 |
| recurrence svt | #29 |
| heparin versus | #29 |
| dabigatran pcc | #29 |
| pulmonary angiography | #29 |
| blind trials | #29 |
| 1000 individuals | #29 |
| authors incidence | #29 |
| pulmonary embolism recurrence | #29 |
| septicemia | #29 |
| acenocoumarol patients | #29 |
| bleeding increased | #29 |
| aspirin placebo | #29 |
| cindexes | #29 |
| aminoglycoside therapy | #29 |
| 1000 personyears incidence | #30 |
| rule patients | #30 |
| administration pentoxifylline | #30 |
| f1 2 | #30 |
| xii factor | #30 |
| prevention venous | #30 |
| cancer venous | #30 |
| new anticoagulants | #30 |
| doac vka | #30 |
| patients vte | #30 |
| ufh vte | #30 |
| residual thrombosis | #30 |
| vte coc | #30 |
| direct oral factor | #30 |
| costs diagnosis | #30 |
| 95 risk | #30 |
| thromboembolism warfarin | #30 |
| support techniques | #30 |
| embolism risk | #30 |
| subcutaneous heparin | #30 |
| markers coagulation activation | #30 |
| imaging sensitivity specificity | #31 |
| apixaban placebo | #31 |
| events 95 | #31 |
| extended prophylaxis | #31 |
| vte ufh | #31 |
| analysis reviewers | #31 |
| 2 antiplasmin | #31 |
| placebo observation | #31 |
| standardtherapy | #31 |
| rfviia novoseven | #31 |
| dvt pulmonary | #31 |
| rhir | #31 |
| thromboprophylaxis risk | #31 |
| prevalence probability | #31 |
| antithrombotic therapies | #31 |
| recurrent patients | #31 |
| ventilation scintigraphy | #31 |
| incidence cteph | #31 |
| incidence pph | #31 |
| women recurrent miscarriage | #31 |
| 8755 | #31 |
| recurrent vte patients | #31 |
| iii activity | #31 |
| ufh fondaparinux | #31 |
| thromboembolism adolescent | #31 |
| experimental endotoxemia | #31 |
| patients deepvein thrombosis | #31 |
| dimer cutoff | #31 |
| inhibitor edoxaban | #31 |
| recurrent episode | #31 |
| term risk | #31 |
| activation blood coagulation | #31 |
| 0206 | #31 |
| bled | #31 |
| pharmacological prophylaxis | #31 |
| factors thrombolytic | #32 |
| suspected patients | #32 |
| negative septicemia | #32 |
| normal genotype | #32 |
| generation patients | #32 |
| age adjusted | #32 |
| year 95 | #32 |
| warfarin vte | #32 |
| negative dimer | #32 |
| resistance activated | #32 |
| low clinical | #32 |
| leiden mutation | #32 |
| international society thrombosis | #32 |
| khorana score patients | #32 |
| factor female | #32 |
| netherlands predictive | #32 |
| treatment anticoagulants | #32 |
| varicosis | #32 |
| ufh | #32 |
| parenteral anticoagulation | #32 |
| parenteral anticoagulants | #32 |
| mega study | #33 |
| thromboembolism young | #33 |
| factor viii patients | #33 |
| subcutaneous male | #33 |
| data meta | #33 |
| activation factors | #33 |
| warfarin risks | #33 |
| chapter patients | #33 |
| anticoagulant protein | #33 |
| cancer patients diagnosis | #33 |
| active implementation | #33 |
| pulmonary angiogram | #33 |
| apixaban treatment | #33 |
| unitage | #33 |
| prophylaxis vte | #33 |
| rhirudin | #33 |
| additional tests | #33 |
| low probability | #33 |
| heparin lmwh | #33 |
| nephrotoxicity gentamicin | #33 |
| plasmin alpha | #34 |
| 9241 | #34 |
| grade 1a | #34 |
| anticoagulant | #34 |
| deficiency protein | #34 |
| subsegmental pulmonary embolism | #34 |
| 10 95 | #34 |
| warfarin adult | #34 |
| 590 | #34 |
| reocclusion patients | #34 |
| control trials | #34 |
| pregnancy loss women | #34 |
| phytonadione | #34 |
| 3 months treatment | #34 |
| bilateral venography | #34 |
| hemorrhage heparin humans | #34 |
| lmwh unfractionated heparin | #34 |
| vte thrombophilia | #34 |
| compare efficacy | #34 |
| thrombosis lower | #34 |
| apcsr | #34 |
| vte compared | #34 |
| lung scanning | #35 |
| neoplasms venous | #35 |
| pph blood loss | #35 |
| patients efficiency | #35 |
| rviia | #35 |
| risk members | #35 |
| weekly subcutaneous | #35 |
| statin association | #35 |
| prevention model | #35 |
| radiologists diagnosis | #35 |
| 36 95 | #35 |
| anticoagulants benzimidazoles | #35 |
| surgery hip | #35 |
| embolism | #35 |
| activation coagulation | #35 |
| enoxaparin prevention | #35 |
| regular monitoring | #36 |
| novoseven | #36 |
| acute symptomatic | #36 |
| hellp patients | #36 |
| inherited risk factors | #36 |
| viii levels | #36 |
| fibrinolytic activation | #36 |
| studies echocardiography | #36 |
| thrombophilia venous | #36 |
| riskbenefit | #36 |
| 287 patients | #36 |
| venous thromboembolism dabigatran | #36 |
| 1698 | #36 |
| treatment acute vte | #36 |
| iii antithrombin | #36 |
| venous thromboembolic disease | #36 |
| 4139 | #36 |
| peripheral endovascular | #36 |
| catheterrelated infection | #36 |
| fibrinogen depletion | #36 |
| dose reduction patients | #36 |
| factors travel | #36 |
| levels coagulation | #36 |
| thrombosis humans | #37 |
| anticoagulants prevention | #37 |
| risk factors pts | #37 |
| pad studies | #37 |
| suspected venous | #37 |
| recombinant hirudin | #37 |
| excluding | #37 |
| genotype 95 | #37 |
| lwmh | #37 |
| factors thrombophilia | #37 |
| bagsvaerd | #37 |
| warfarin 95 | #37 |
| screening occult | #37 |
| cumulative incidence vte | #37 |
| anticoagulant action | #37 |
| tat complexes | #37 |
| prophylactic heparin | #37 |
| venography | #37 |
| magellan | #37 |
| ototoxicity nephrotoxicity | #37 |
| perelated mortality | #37 |
| outcome composite | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| ctpa patients | #37 |
| risk venous thrombosis | #37 |
| vte increased | #37 |
| patients ddimer levels | #38 |
| congenital deficiencies | #38 |
| sensitivity biomarkers | #38 |
| 2835 | #38 |
| 3306 | #38 |
| doac lmwh | #38 |
| anticoagulants female humans | #38 |
| submassive pulmonary | #38 |
| age recurrence | #38 |
| fetal loss women | #38 |
| recurrence day | #38 |
| vte bleeding | #38 |
| coagulation protein | #38 |
| catheterrelated thrombosis | #38 |
| vte cancer patients | #38 |
| rivaroxaban placebo | #38 |
| restenosis reocclusion | #38 |
| nonmajor bleeding | #38 |
| 10 total | #38 |
| low molecular weight | #39 |
| incidence patients | #39 |
| systemic inflammatory responses | #39 |
| embolus | #39 |
| subcutaneous intention | #39 |
| submassive | #39 |
| doacs | #39 |
| 277 patients | #39 |
| incidence cancer | #39 |
| diagnostic prediction | #39 |
| enoxaparin placebo | #39 |
| children familial hypercholesterolemia | #39 |
| time compression | #39 |
| superficial vein thrombosis | #39 |
| heparins lmwhs | #39 |
| septic syndrome | #39 |
| specificity patients | #39 |
| compression stocking | #39 |
| continued treatment | #39 |
| fibrin fibrinogen | #39 |
| anticoagulation therapy patients | #40 |
| common femoral vein | #40 |
| patients normal | #40 |
| endotoxininduced | #40 |
| therapeutic dosages | #40 |
| pemb | #40 |
| grade 1a patients | #40 |
| anticoagulant therapy | #40 |
| dalteparin treatment | #40 |
| clotting activation | #40 |
| day 6 months | #40 |
| thrombinantithrombin complexes | #40 |
| activatable fibrinolysis | #40 |
| tfmp | #40 |
| bleeding | #40 |
| standardized definition | #40 |
| fviiic | #40 |
| arterial vascular | #40 |
| international clinical | #40 |
| ambulatory cancer | #40 |
| episode venous thromboembolism | #40 |
| placebo 6 months | #41 |
| cancer lmwh | #41 |
| risk recurrent vte | #41 |
| endotoxin induced | #41 |
| lung scintigraphy | #41 |
| dabigatran etexilate | #41 |
| triage tests | #41 |
| calf vein thrombosis | #41 |
| submassive pulmonary embolism | #41 |
| heparin therapy | #41 |
| lowmolecularweight heparins | #41 |
| pentasaccharides | #41 |
| anticoagulated patients | #41 |
| 95 genotype | #41 |
| 7268 | #41 |
| anticoagulation risk | #42 |
| prophylaxis venous | #42 |
| thrombosis administration | #42 |
| netilmicin | #42 |
| patients vasopressors | #42 |
| standardization committee | #42 |
| neoplasms thrombosis | #42 |
| type graft | #42 |
| patients prospective | #42 |
| cell extravasation | #42 |
| patients silent | #42 |
| 8101 | #42 |
| stroke thrombosis | #42 |
| major contributor | #42 |
| warfarin anticoagulants | #43 |
| rtap | #43 |
| monthly incidence | #43 |
| cancer adjusted | #43 |
| fetal loss | #43 |
| patients vte risk | #43 |
| 543 patients | #43 |
| ischemic events | #43 |
| probability patients | #43 |
| initial treatment | #43 |
| venous thromboembolism vte | #43 |
| draft document | #43 |
| venous thrombosis thrombophilia | #43 |
| post‐thrombotic syndrome | #43 |
| heparin risk | #43 |
| vkas patients | #43 |
| patients tinzaparin | #44 |
| restoration euthyroidism | #44 |
| recurrent vte 95 | #44 |
| edoxaban therapy | #44 |
| efficiency models | #44 |
| uedvt patients | #44 |
| protein sepsis | #44 |
| experimental venous thrombosis | #44 |
| expert physicians | #44 |
| role coagulation | #44 |
| indications patients | #44 |
| nonvka oral anticoagulants | #44 |
| mild hyperhomocysteinaemia | #44 |
| enoxaparin risk | #44 |
| rate venous | #44 |
| 10–14 | #44 |
| 20 30 | #44 |
| factors thromboembolism | #44 |
| 95 pulmonary embolism | #44 |
| venous thrombotic | #45 |
| 95 warfarin | #45 |
| wells score | #45 |
| years algorithm | #45 |
| dose adjusted | #45 |
| revascularisation procedures | #45 |
| fondaparinux patients | #45 |
| oral direct | #45 |
| patients bnp | #45 |
| coumarin therapy | #45 |
| coagulation activation | #45 |
| dvt patients | #45 |
| treated warfarin | #45 |
| dose lmwh | #45 |
| stroke risk assessment | #46 |
| extended duration | #46 |
| abtpo | #46 |
| standard therapy | #46 |
| hospital outpatients | #46 |
| ruling | #46 |
| pioped | #46 |
| treatment model | #46 |
| bleeding rivaroxaban | #46 |
| percent confidence | #46 |
| patients unprovoked vte | #46 |
| healthcare settings | #46 |
| day levels | #46 |
| daily rivaroxaban | #46 |
| prothrombin fragment f1 | #46 |
| major bleeding placebo | #46 |
| ssc isth | #46 |
| management venous | #46 |
| plasma ddimer levels | #47 |
| mutation pregnancy | #47 |
| iiia receptors | #47 |
| new oral anticoagulant | #47 |
| outcome vitamin | #47 |
| central venous lines | #47 |
| ambulatory anticoagulants | #47 |
| roccurve | #47 |
| male methimazole | #47 |
| episode vte | #47 |
| boehringer ingelheim | #47 |
| mechanical prophylaxis | #47 |
| bristol myers squibb | #47 |
| risk recurrent | #48 |
| recurrence venous thromboembolism | #48 |
| patients pulmonary | #48 |
| small studies | #48 |
| diagnosis physicians | #48 |
| intermediate risk risk | #48 |
| fondaparinux heparin | #48 |
| patients acute dvt | #48 |
| travel risk | #48 |
| thromboprophylactic | #48 |
| elevated plasma levels | #48 |
| subcommittee | #48 |
| daiichi | #48 |
| thrombotic burden | #48 |
| rivaroxaban compared | #48 |
| factors rivaroxaban | #48 |
| women aspirin | #49 |
| factor viii deficiency | #49 |
| vte diagnosis | #49 |
| rivaroxaban prevention | #49 |
| calf vein | #49 |
| levels protein | #49 |
| lowmolecularweight heparin lmwh | #49 |
| enoxaparin | #49 |
| intensity treatment | #50 |
| treatment threshold | #50 |
| incidence venous thromboembolism | #50 |
| buller | #50 |
| nonselective betablockers | #50 |
| outpatient therapy | #50 |
| prospective diagnostic | #50 |
| cardiac surgery mortality | #50 |
| acute respiratory insufficiency | #50 |
| dvt diagnosis | #50 |
| transient risk factor | #50 |
| atria patients | #50 |
| etexilate | #50 |
| vitamink antagonists | #50 |
| thromboembolism aged | #50 |
| effects coagulation | #51 |
| discrimination model | #51 |
| protein deficiencies | #51 |
| patients 11 | #51 |
| previous survey | #51 |
| global disease | #51 |
| acenocoumarol | #51 |
| factor vte | #51 |
| strategies treatment | #51 |
| tomography pulmonary | #51 |
| normal perfusion | #51 |
| 95 apixaban | #51 |
| pdvt | #52 |
| lmwh fondaparinux | #52 |
| 3 month | #52 |
| apixaban vte | #52 |
| lung scans | #52 |
| hematologic malignancies patients | #52 |
| vte major bleeding | #52 |
| inhibitors heparin | #52 |
| doacs vka | #52 |
| 1·12 | #52 |
| svt patients | #52 |
| risk venous thromboembolism | #52 |
| unnecessarily | #52 |
| patients comorbid conditions | #52 |
| free thyroxine ft4 | #52 |
| warfarintreated patients | #53 |
| hemostatic balance | #53 |
| 479 patients | #53 |
| absolute risks | #53 |
| thrombophilic factors | #53 |
| 40 daily | #53 |
| reported incidence | #53 |
| cross study | #53 |
| 1522 | #53 |
| suspected venous thromboembolism | #53 |
| preference patients | #53 |
| versus enoxaparin | #53 |
| thromboembolism prevention | #53 |
| patients initially | #53 |
| postthrombotic syndrome | #53 |
| major bleeds | #54 |
| 034 | #54 |
| 378 patients | #54 |
| endocrine disorders | #54 |
| familial thrombophilia | #54 |
| vte mortality | #54 |
| antithrombotic drug | #54 |
| male pulmonary embolism | #54 |
| bled score | #54 |
| patients obese | #54 |
| thromboembolism death | #54 |
| patients incidence | #54 |
| acquired risk factors | #54 |
| pai1 levels patients | #54 |
| chads2 cha2ds2vasc | #54 |
| prethrombotic | #54 |
| 2537 | #54 |
| methods randomized | #55 |
| insurances | #55 |
| anticoagulants arthroplasty replacement | #55 |
| long term risk | #55 |
| biological pan | #55 |
| dosereduction | #55 |
| legs patients | #55 |
| unfractionated heparin ufh | #55 |
| rivaroxaban | #55 |
| nondeficient | #55 |
| unfractionated heparin | #55 |
| treatment thresholds | #55 |
| compared lmwh | #55 |
| proximal extent | #55 |
| major bleeding apixaban | #56 |
| risk major bleeding | #56 |
| level mortality | #56 |
| physicians guidelines | #56 |
| seventh accp conference | #56 |
| vitamin warfarin | #56 |
| enoxaparin rivaroxaban | #56 |
| inr values | #56 |
| deficiency prevalence | #56 |
| preeclampsia hellp syndrome | #56 |
| 20210a | #56 |
| reduced capacity | #56 |
| time event | #56 |
| vte death | #56 |
| tromboembólica | #56 |
| vasopressors | #56 |
| enoxaparin patients | #56 |
| weight heparins | #56 |
| venous outflow obstruction | #56 |
| ctscan | #57 |
| calf dvt | #57 |
| subsegmental pulmonary | #57 |
| inhibitors female humans | #57 |
| levels survival | #57 |
| antithrombin iii heparin | #57 |
| clinical models | #57 |
| risk factors vte | #57 |
| thrombin activatable | #58 |
| inhibitors female | #58 |
| lowmolecular weight heparin | #58 |
| pharmo | #58 |
| doacs patients | #58 |
| unfractionated heparin patients | #58 |
| ruled | #58 |
| malignancy mortality | #58 |
| fibrinolysis humans | #58 |
| spiral computed | #58 |
| aventis | #59 |
| clot lysis time | #59 |
| warfarin treatment | #59 |
| risk vte | #59 |
| bias trial | #59 |
| heterozygous factor | #59 |
| mutation prothrombin | #59 |
| factor generation | #59 |
| thrombosis aged | #59 |
| acute venous thromboembolism | #59 |
| direct oral | #59 |
| risk factors sensitivity | #59 |
| safety warfarin | #59 |
| incidence symptomatic | #59 |
| risk periods | #59 |
| acute pulmonary embolism | #60 |
| 079 95 | #60 |
| target inr | #60 |
| anticoagulants treatment | #60 |
| awareness risk factors | #60 |
| prevalence pulmonary | #60 |
| hemorrhage humans | #60 |
| women difference | #60 |
| pulmonary embolism 95 | #60 |
| pediatric venous thromboembolism | #60 |
| constans | #60 |
| atrial fibrillation metaanalysis | #60 |
| fixeddose | #60 |
| benzimidazoles dabigatran | #61 |
| dvt 95 | #61 |
| rosendaal | #61 |
| free thyroxine | #61 |
| tests prevalence | #61 |
| association protein | #61 |
| cdr score | #61 |
| long‐term treatment | #61 |
| 3633 | #61 |
| month surgery | #61 |
| hypocoagulable | #61 |
| perfusion ventilation | #61 |
| amuse | #61 |
| human endotoxemia | #62 |
| 273 patients | #62 |
| patients administration | #62 |
| post thrombotic | #62 |
| ttr patients | #62 |
| procoagulant state | #62 |
| activated partial | #62 |
| informatizado | #62 |
| general practitioners patients | #62 |
| protein fibrinogen | #62 |
| 250 patients | #62 |
| combined contraceptives oral | #62 |
| venous thromboembolisms | #63 |
| treatment network | #63 |
| 33 women | #63 |
| injection endotoxin | #63 |
| vte thromboprophylaxis | #63 |
| common odds ratio | #63 |
| rivaroxaban lmwh | #63 |
| revised geneva score | #63 |
| women mutations | #63 |
| physicians predictive | #63 |
| symptoms dvt | #63 |
| cvrs | #63 |
| smoking smoking cessation | #63 |
| factor leiden risk | #63 |
| management anticoagulation | #63 |
| quantitative test | #63 |
| decision rules | #64 |
| cancer noncancer patients | #64 |
| selfadjustment | #64 |
| acute pulmonary | #64 |
| oral thrombin | #64 |
| superficial vein | #64 |
| thrombophilic risk | #64 |
| patients aortic valve | #64 |
| prior vte | #64 |
| bleeding events patients | #64 |
| blinded trial | #64 |
| heparin fondaparinux | #64 |
| vkas treatment | #64 |
| factor inhibitors | #64 |
| dvts | #64 |
| postthrombotic | #64 |
| prothrombin g20210a mutation | #65 |
| stroke thromboembolism | #65 |
| prevalence abnormalities | #65 |
| accuracy diagnostic tests | #65 |
| fvl vte | #65 |
| ultrasonograms | #65 |
| treatment pad | #65 |
| newer anticoagulants | #66 |
| dvt sensitivity | #66 |
| axa | #66 |
| elfa | #66 |
| female heparin | #66 |
| risk factor thrombosis | #66 |
| 95 bleeding | #66 |
| 0 points | #66 |
| statin therapy risk | #66 |
| death classification | #66 |
| rapid triage | #66 |
| atrial fibrillation stroke | #67 |
| rate major | #67 |
| standard therapy patients | #67 |
| patients factor | #67 |
| patients tertiles | #67 |
| 1127 | #67 |
| apixaban | #67 |
| 20210g | #68 |
| 3594 | #68 |
| patients bnp levels | #68 |
| patients benefits | #68 |
| perioperative blood | #68 |
| 05 95 | #68 |
| fibrinolytic | #68 |
| 1894 | #68 |
| ranging study | #68 |
| academic medical centre | #68 |
| coagulation fibrinolysis | #68 |
| postphlebitic | #69 |
| thrombosis blood | #69 |
| plasma interleukin | #69 |
| suspected | #69 |
| ionis | #69 |
| recurrent thrombosis patients | #69 |
| certoparin | #69 |
| heparin ufh | #69 |
| justify | #69 |
| enfermedad tromboembólica | #69 |
| major bleeding complications | #70 |
| cutoff levels | #70 |
| 8190 | #70 |
| mantelhaenszel | #70 |
| gramnegative sepsis | #70 |
| withhold | #70 |
| rivaroxaban treatment | #70 |
| ischemic events patients | #70 |
| vwfrco | #70 |
| thrombosis recurrence | #70 |
| patients protein | #70 |
| aged predictive | #70 |
| elevated cardiac | #70 |
| fixed dose | #70 |
| test patients | #70 |
| α2ap | #70 |
| asymptomatic atherosclerosis | #71 |
| diagnostic sensitivity specificity | #71 |
| thromboprophylaxis | #71 |
| topic costs | #71 |
| levels vwf | #71 |
| unfractionated | #71 |
| clopidogrel placebo | #71 |
| vte vka | #71 |
| tests prospective | #71 |
| plasminogen plg | #71 |
| viia factor | #72 |
| ddimer values | #72 |
| trifurcation | #72 |
| pooled rate | #72 |
| overt hypothyroidism | #72 |
| activation prothrombin | #72 |
| patients lmwh | #72 |
| elevated factor | #72 |
| antithrombin iii iii | #72 |
| complications hematologic | #72 |
| hf studies | #72 |
| versus vitamin | #72 |
| new anticoagulant | #72 |
| ingelheim | #73 |
| analysis diagnostic | #73 |
| 12 months 95 | #73 |
| tomography spiral | #73 |
| ddimer measurement | #73 |
| soluble fibrin | #73 |
| prolongations | #73 |
| noacs | #73 |
| reversal agent | #73 |
| soluble thrombomodulin | #74 |
| longterm risk | #74 |
| experimental metastasis | #74 |
| study selection | #74 |
| carriers | #74 |
| proteins patients | #74 |
| female hemorrhage | #74 |
| suspected dvt | #74 |
| prethrombotic state | #74 |
| 2550 | #74 |
| dvt study | #74 |
| 2124 | #74 |
| 1732 | #74 |
| 5395 | #74 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| selective factor | #75 |
| 2904 | #75 |
| retrospective follow | #75 |
| incidence bleeding events | #75 |
| 1334 | #75 |
| thrombolytic therapy patients | #75 |
| postoperative dvt | #75 |
| factor xii deficiency | #76 |
| extended anticoagulation | #76 |
| combined contraceptives | #76 |
| tests primary | #76 |
| oral combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| angiography ctpa | #76 |
| risk thrombosis | #76 |
| early time | #76 |
| social aspects | #77 |
| thrombosis pregnancy | #77 |
| individual patient | #77 |
| patients secondary | #77 |
| p023 | #77 |
| boehringer | #77 |
| arterial thromboembolism | #78 |
| unprovoked | #78 |
| ipg | #78 |
| women thrombophilia | #78 |
| elevated dimer | #78 |
| female fibrinolysis | #78 |
| arterial wall thickness | #78 |
| 20 daily | #78 |
| vkas | #79 |
| humans pulmonary | #79 |
| efficacy agents | #79 |
| factor adult | #79 |
| suspected acute | #79 |
| time therapeutic | #79 |
| limulus test | #79 |
| topic heparin | #79 |
| 2486 | #79 |
| vte fvl | #79 |
| daily bid | #80 |
| patient data | #80 |
| thromboembolism incidence | #80 |
| alife | #80 |
| validation models | #80 |
| subhazard ratio | #80 |
| bleeding mortality | #80 |
| vte rate | #80 |
| 95 05 | #80 |
| sspe patients | #80 |
| heterozygous deficiency | #80 |
| suspected cancer | #80 |
| test evaluation | #81 |
| weitz | #81 |
| systemic inflammatory | #81 |
| outpatient basis | #81 |
| prothrombin complex concentrate | #81 |
| lmwh vte | #81 |
| topic risk | #81 |
| vascular events | #81 |
| knee arthroplasty patients | #81 |
| walking distance | #81 |
| thrombosis incidence | #82 |
| posthoc analysis | #82 |
| common practice | #82 |
| thrombolytic drugs | #82 |
| clinical sign | #82 |
| 50 micrograms | #82 |
| placebo women | #82 |
| 3month followup | #82 |
| prospective validation | #82 |
| thrombosis thrombophilia | #82 |
| mammography patients | #82 |
| crnmb | #82 |
| heparin prevention | #82 |
| symptomatic carriers | #82 |
| timeperiods | #82 |
| dimer patients | #83 |
| inhibitor dabigatran | #83 |
| elective coronary | #83 |
| 2213 | #83 |
| patients thrombi | #83 |
| bleeding women | #83 |
| bistro | #83 |
| 287 | #83 |
| screening humans | #84 |
| heparin treatment | #84 |
| inherited thrombophilia | #84 |
| duration therapy | #84 |
| diagnostic outcome | #84 |
| inhibitor rivaroxaban | #84 |
| prophylactic dose | #84 |
| normotensive patients | #84 |
| healthcare setting | #84 |
| venous thrombosis patients | #85 |
| asymptomatic dvt | #85 |
| antithrombin iii protein | #85 |
| endotoxins | #85 |
| thrombosis svt | #85 |
| peripheral vascular diseases | #85 |
| normal levels | #85 |
| anticoagulants antiphospholipid | #85 |
| elevated ddimer levels | #86 |
| 4576 | #86 |
| 10⁶ | #86 |
| dabigatran vka | #86 |
| venovenous hemofiltration | #86 |
| 75 microg | #86 |
| major bleeding warfarin | #86 |
| rhapc | #86 |
| post‐hoc analysis | #87 |
| obstetric patients | #87 |
| 95 100 | #87 |
| ≤50 | #87 |
| contact activation | #87 |
| avws | #87 |
| patients 28 | #87 |
| clinical impact | #87 |
| vidas | #87 |
| acute venous | #87 |
| activation factor | #88 |
| cdr | #88 |
| 3319 | #88 |
| venographic | #88 |
| 4 points | #88 |
| internist | #88 |
| washout period | #88 |
| aged multicenter | #88 |
| treatment incidence | #88 |
| lmwhs | #88 |
| treatment statins | #88 |
| severe hf | #89 |
| costs patient | #89 |
| vte venous thromboembolism | #89 |
| matisse | #89 |
| reversal strategies | #89 |
| ddimer | #89 |
| beta blockers | #89 |
| ventilation lung | #89 |
| safety noacs | #89 |
| unexplained recurrent | #89 |
| anticoagulants dabigatran | #89 |
| adequate treatment | #89 |
| stroke bleeding | #89 |
| tests test | #89 |
| cytokine release | #89 |
| rates major bleeding | #89 |
| smoking incidence | #89 |
| new patients | #90 |
| primary thromboprophylaxis | #90 |
| outweighs | #90 |
| thrombophilic risk factors | #90 |
| vka dabigatran | #90 |
| 2293 | #90 |
| fibrinolytic factors | #90 |
| popliteal vein | #90 |
| pediatric venous | #90 |
| venous thrombosis risk | #90 |
| pyridines pyridones | #91 |
| anticoagulants doacs | #91 |
| agents hemorrhage | #91 |
| 60 95 | #91 |
| 20210 | #91 |
| thrombosis women | #91 |
| perfusion ratio | #91 |
| thromboembolism pregnancy | #91 |
| inconvenience | #91 |
| cdrs | #91 |
| single intravenous | #92 |
| thrombotic disease | #92 |
| combined clinical | #92 |
| prophylaxis incidence | #92 |
| rivaroxaban edoxaban | #93 |
| 95 years | #93 |
| scenario analyses | #93 |
| direct thrombin inhibitors | #93 |
| compression patients | #93 |
| incidence knee | #93 |
| anticoagulation reversal | #93 |
| children vte | #94 |
| 1027 | #94 |
| patients symptomatic | #94 |
| test result | #94 |
| 125 patients | #94 |
| vte surgery | #94 |
| atherogenic lipid | #94 |
| hf severity | #94 |
| heparins | #94 |
| direct oral anticoagulant | #95 |
| 2 levels | #95 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| 6 12 months | #96 |
| symptomatic vte | #96 |
| ddimer level | #96 |
| xii deficiency | #96 |
| randomised crossover study | #96 |
| fondaparinux treatment | #96 |
| risk symptomatic | #96 |
| efficacy rivaroxaban | #96 |
| abnormal perfusion | #97 |
| tpa release | #97 |
| difference rates | #97 |
| invasive testing | #97 |
| doacs risk | #97 |
| pyrazoles pyridones | #97 |
| haemophilia patients | #97 |
| symptomatic pulmonary embolism | #97 |
| studies evaluated | #97 |
| fibrin generation | #97 |
| activated protein apc | #98 |
| supervised exercise therapy | #98 |
| hypercoagulable | #98 |
| essential thrombocythaemia | #98 |
| major bleed | #98 |
| pregnancy postpartum period | #98 |
| simplify | #98 |
| 2875 | #98 |
| 16slice | #98 |
| probast | #99 |
| unselected | #99 |
| lmwh warfarin | #99 |
| perfusion scintigraphy | #99 |
| hirudin | #99 |
| acute dvt | #99 |
| risk arterial | #99 |
| 2·0 | #99 |
| gbd 2010 | #100 |
| 3 trials | #100 |
| doubleblind trial | #100 |
| previews | #100 |
| 1116 | #100 |
| fatty foods | #100 |
| increasing levels | #100 |
| warfarin patients | #100 |
| patient groups | #100 |
| prevention recurrent | #100 |
| aptts | #101 |
| morpholines | #101 |
| factor viia | #101 |
| factor vii factor | #101 |
| 40 microg | #102 |
| venous thromboembolism women | #102 |
| 265 patients | #102 |
| alternative diagnosis | #102 |
| enoxaparin fondaparinux | #102 |
| pts patients | #102 |
| low pretest probability | #102 |
| 338 | #103 |
| arthroscopic anterior | #103 |
| therapeutic consequences | #103 |
| adjudicated | #103 |
| endogenous thrombin | #103 |
| pregnancy puerperium | #103 |
| doppler method | #103 |
| cteph patients | #103 |
| term treatment | #104 |
| oral factor | #104 |
| absolute increase | #104 |
| antithrombin iii | #104 |
| fibrin degradation products | #104 |
| partial restoration | #104 |
| assay variation | #104 |
| recurrence women | #104 |
| apparent increase | #104 |
| diagnostic imaging humans | #104 |
| heparin pregnancy | #104 |
| separate analyses | #104 |
| 1089 | #105 |
| conventional therapy patients | #105 |
| embryo loss | #105 |
| 7 children | #105 |
| 314 | #106 |
| blind double | #106 |
| elevated levels | #106 |
| fibrinolytic systems | #106 |
| chest ray | #106 |
| essentials | #106 |
| study total | #106 |
| hospitalized patients hf | #106 |
| 2479 | #106 |
| thromboprophylaxis patients | #106 |
| thrombosis age | #106 |
| thrombophilia | #106 |
| survival cancer patients | #107 |
| thromboembolic | #107 |
| definition classification | #107 |
| simplified version | #107 |
| vte risk | #107 |
| ddimer levels | #107 |
| topic recurrence | #107 |
| human volunteers | #108 |
| patients cancer | #108 |
| post thrombotic syndrome | #108 |
| cardiovascular death stroke | #108 |
| noncancer patients | #108 |
| grade 1c | #108 |
| specific subgroups | #108 |
| thrombin antithrombin | #109 |
| routine coagulation | #109 |
| 039 | #109 |
| synthetic pentasaccharide | #109 |
| viia | #109 |
| embolism treatment | #109 |
| 500μg | #109 |
| evaluation studies | #109 |
| factor mutation | #109 |
| anticoagulants cohort | #109 |
| 1235 | #109 |
| vka doac | #110 |
| embolism quality | #110 |
| antiplasmin | #110 |
| cancer activity | #110 |
| primary safety | #110 |
| subsequent pregnancy | #110 |
| thrombosis treated | #110 |
| inferiority trial | #110 |
| humans intermittent | #111 |
| negative predictive 100 | #111 |
| siset | #111 |
| comparison control | #111 |
| predefined | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| obstetric complications | #111 |
| epidemiology risk factors | #112 |
| publication anticoagulants | #112 |
| emergency situations | #112 |
| recurrence treatment | #112 |
| chromogenic | #112 |
| efficacy prevention | #112 |
| risk rivaroxaban | #112 |
| topic guidelines | #112 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| thromboembolic diseases | #112 |
| patients 70 | #112 |
| inappropriate treatment | #113 |
| nonionic contrast | #113 |
| heterozygous carriers | #113 |
| metabolic response | #113 |
| lmwh risk | #113 |
| patients nephrotoxicity | #113 |
| postphlebitic syndrome | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| dialysers | #114 |
| study centre | #114 |
| total knee replacement | #114 |
| 0·0 | #114 |
| global public | #115 |
| fibrinogen vwf | #115 |
| patients recurrent | #115 |
| 393 | #115 |
| positive predictive values | #115 |
| hyperhomocysteinaemia | #115 |
| heparin warfarin | #116 |
| topic dabigatran | #116 |
| anticoagulants arthroplasty | #116 |
| agents heparin | #116 |
| computed tomography patients | #116 |
| major bleeding 95 | #116 |
| vte data | #116 |
| reference standard | #116 |
| effects tnf | #116 |
| women severe preeclampsia | #116 |
| life treatment | #116 |
| vte children | #117 |
| protein resistance | #117 |
| 2460 | #117 |
| vte complications | #117 |
| women caesarean | #117 |
| protein inhibitor pci | #117 |
| fibrinolytic parameters | #117 |
| arthroscopies | #117 |
| 2744 | #118 |
| 4118 | #118 |
| proximal dvt | #118 |
| patients extensive | #118 |
| arterial thrombosis patients | #118 |
| autopsyconfirmed | #118 |
| compression stockings | #119 |
| compared warfarin | #119 |
| humans leg | #119 |
| patients doac | #119 |
| incidence pulmonary embolism | #119 |
| healthy humans | #120 |
| lactoferrin leukocyte | #120 |
| dabigatran factor | #120 |
| risk thromboembolism | #120 |
| acquired deficiency | #120 |
| rivaroxaban patients | #120 |
| thrombosis study | #120 |
| previous vte | #120 |
| mortality diseases | #120 |
| months follow | #120 |
| thrombocytopenia thrombosis | #121 |
| patients prostatic cancer | #121 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| studies venous | #122 |
| anti factor | #122 |
| oral hormonal | #122 |
| 100 patients | #123 |
| minor bleeding | #123 |
| heparin | #123 |
| venous thromboembolism pregnancy | #123 |
| acute infection | #123 |
| placebo standard | #123 |
| heparin hirudin | #123 |
| factor xia | #123 |
| early dynamics | #123 |
| ft4 levels | #124 |
| thrombophilia pregnancy | #124 |
| treatment data | #124 |
| vte lmwh | #124 |
| association level | #124 |
| statin risk | #124 |
| atherogenic lipid profile | #124 |
| skin perfusion | #125 |
| incidence thrombosis | #125 |
| diseases mortality | #125 |
| treatment indication | #125 |
| intravenous heparin | #125 |
| bayer | #125 |
| nonsignificantly | #125 |
| thromboembolism recurrence | #125 |
| fibrinolysis inhibitor | #125 |
| elevated liver enzymes | #125 |
| peripheral arterial disease | #125 |
| puerperal disorders | #125 |
| distal dvt | #126 |
| doacs treatment | #126 |
| upper extremity | #126 |
| patients ventilation | #127 |
| patients permanent | #127 |
| marder | #127 |
| occurrence vte | #127 |
| performance scores | #127 |
| unacceptably | #127 |
| thromboprophylaxis lmwh | #127 |
| patients conventional therapy | #128 |
| development vte | #128 |
| direct factor | #128 |
| 50 age | #128 |
| prevention | #128 |
| treatment months | #128 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| 1041 | #129 |
| elevated biomarkers | #129 |
| 060 | #129 |
| mortality cancer patients | #129 |
| riete registry | #129 |
| ctrough | #129 |
| plaster cast | #130 |
| 194 patients | #130 |
| hospital discharge records | #130 |
| patients episode | #130 |
| day 10 | #130 |
| anticoagulants antithrombins | #130 |
| 220 | #130 |
| internists | #130 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| obviating | #131 |
| pooled incidence | #131 |
| 05 patients | #131 |
| tests specificity | #131 |
| rivaroxaban versus | #132 |
| postpartum period women | #132 |
| hoc analysis | #132 |
| hypocoagulability | #132 |
| fxa inhibitors | #133 |
| direct inhibitors | #133 |
| 80 anticoagulants | #133 |
| cha2ds2vasc | #133 |
| started | #133 |
| avidin | #133 |
| enoxaparin treatment | #133 |
| selectin levels | #134 |
| instituted | #134 |
| pulmonary angiography patients | #134 |
| rco vwf | #134 |
| risk pad | #134 |
| embolism acute | #134 |
| bnp concentration | #135 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| months anticoagulation | #136 |
| severe pph | #136 |
| 0056 | #136 |
| followup patients | #136 |
| east asian patients | #136 |
| thrombotic syndrome | #136 |
| apixaban edoxaban | #136 |
| clinical prediction | #136 |
| point‐of‐care | #137 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| sequential application | #137 |
| factor prothrombin | #137 |
| diagnostic work | #137 |
| phase 3 trials | #137 |
| 2283 | #137 |
| bleeding warfarin | #138 |
| national guidelines | #138 |
| complete inhibition | #138 |
| studies mortality | #138 |
| intravascular coagulation dic | #138 |
| antidote | #138 |
| enhanced factor | #138 |
| risk fatal | #139 |
| oral anticoagulant treatment | #139 |
| factor viii factor | #139 |
| reproducibility risk | #139 |
| 2465 | #139 |
| patients comparison | #139 |
| 3 weeks | #139 |
| direct inhibitor | #139 |
| 95 major bleeding | #139 |
| 80 cohort | #140 |
| 12 95 | #140 |
| human activated | #140 |
| vwf rco | #140 |
| ottawa | #140 |
| 20 iu | #140 |
| distal deep | #140 |
| 0114 | #140 |
| dvt incidence | #140 |
| pharmacy records | #141 |
| thromboembolic disorders | #141 |
| antidotes | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| geneva | #143 |
| treatment pulmonary | #143 |
| points 95 | #143 |
| ischaemic events | #143 |
| jugular veins | #143 |
| active malignancy | #143 |
| warfarin administration | #143 |
| escherichia humans | #143 |
| postoperative venous | #144 |
| doac treatment | #144 |
| fatal pulmonary | #144 |
| topic practice patterns | #144 |
| compared treatment | #144 |
| pregnancy female humans | #144 |
| management vte | #144 |
| thrombosis model | #145 |
| patient populations | #145 |
| serial testing | #145 |
| referred patients | #145 |
| filters venous | #145 |
| hyperthyroxinemia | #145 |
| dose rivaroxaban | #145 |
| protein factor | #146 |
| derived microvesicles | #146 |
| death cancer patients | #146 |
| months treatment | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| embolism diagnosis | #148 |
| rebuttal | #148 |
| antithrombotic drugs | #148 |
| intention treat | #148 |
| long‐acting | #148 |
| 2076 | #148 |
| partial thromboplastin | #148 |
| acute medical illness | #148 |
| 10 years patients | #148 |
| procoagulant | #149 |
| thrombocyte | #149 |
| risk subgroups | #149 |
| 0·45 | #149 |
| individual patient data | #149 |
| vte hospitalization | #149 |
| relevant publications | #149 |
| diagnostic score | #149 |
| dimer level | #150 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| coagulation dic | #151 |
| humans injections | #151 |
| patient eligibility | #152 |
| patients primary outcome | #152 |
| longterm treatment | #152 |
| bleeding patients | #152 |
| continuous venovenous | #152 |
| extracorporeal circuit | #153 |
| thrombosis prevention | #153 |
| point systems | #153 |
| hypercoagulable state | #153 |
| cardiopulmonary bypass surgery | #153 |
| bleeding scores | #154 |
| dimer levels | #154 |
| active cancer | #154 |
| thrombosis factor | #154 |
| direct thrombin | #154 |
| activity mortality | #154 |
| angioplasty patients | #154 |
| warfarin apixaban | #155 |
| drug factor | #155 |
| tomography patients | #155 |
| curve sensitivity | #155 |
| fiia | #155 |
| states venous | #155 |
| thromboembolic event | #155 |
| patients gastrointestinal | #156 |
| recurrent symptoms | #156 |
| coagulant activity | #156 |
| 09 | #156 |
| stockings | #156 |
| fvl | #156 |
| daily oral | #156 |
| vte treatment | #156 |
| enoxaparin dose | #156 |
| hemodynamically | #157 |
| increased thrombin | #157 |
| prophylaxis patients | #157 |
| cross‐sectional survey | #157 |
| dfl | #158 |
| underlying malignancy | #158 |
| months chemotherapy | #158 |
| 2126 | #158 |
| duration anticoagulation | #158 |
| 97 | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| 120 minutes | #160 |
| thrombotic disorders | #160 |
| children fh | #160 |
| guidelines prevention | #160 |
| schering | #160 |
| 145 patients | #160 |
| antithrombotic efficacy | #160 |
| antagonists patients | #161 |
| pvo | #161 |
| prophylactics | #161 |
| patients imaging | #162 |
| incidence vte | #162 |
| lysine analogues | #162 |
| 2206 | #162 |
| women time | #162 |
| factors bleeding | #163 |
| increased plasma levels | #163 |
| rates vte | #163 |
| venous thrombus | #163 |
| 198 patients | #163 |
| strain gauge | #163 |
| imaging test | #163 |
| coagulation blood | #163 |
| lmwh therapy | #163 |
| 028 | #164 |
| age comorbidity | #164 |
| inborn humans | #164 |
| justified | #164 |
| observer variability | #164 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| subhazard | #165 |
| mutation factor | #165 |
| microvascular thrombosis | #166 |
| phlebography | #166 |
| stockings compression | #166 |
| management venous thromboembolism | #166 |
| pravastatin therapy | #166 |
| viii factor | #166 |
| strategies patients | #166 |
| recurrent thrombosis | #167 |
| 3658 | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| recurrent acute | #168 |
| syndrome pts | #168 |
| treatment 3 months | #168 |
| cvcs | #168 |
| cstatistics | #168 |
| double heterozygosity | #168 |
| warfarin | #168 |
| current clinical practice | #168 |
| therapeutic range | #169 |
| preexistent | #169 |
| fold increased | #169 |
| 3 12 | #169 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| patients infections | #169 |
| thrombosis cancer | #170 |
| interobserver agreement | #170 |
| cart patients | #170 |
| postoperative blood loss | #170 |
| heavy menstrual bleeding | #170 |
| aged algorithms | #171 |
| 57 years | #171 |
| venous thrombotic events | #171 |
| adamts‐13 | #171 |
| recombinant factor | #171 |
| patients blood transfusion | #172 |
| risk factors patients | #172 |
| lmw heparin | #172 |
| antifibrinolytic | #172 |
| pulmonology | #172 |
| clinical trials patients | #172 |
| vaginal bleeding | #172 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| inr | #173 |
| bleeds | #173 |
| arterial occlusions | #174 |
| clinically bleeding | #174 |
| laboratory monitoring | #174 |
| bleeding tendency | #174 |
| patients initial | #174 |
| fragment 1 | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| vte common | #175 |
| data control | #175 |
| prothrombin | #177 |
| picotamide | #177 |
| mitsubishi | #177 |
| short‐ | #178 |
| aspirin ticlopidine | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| intention analysis | #178 |
| noninferior | #179 |
| baseline day | #179 |
| oral female humans | #179 |
| vte event | #179 |
| concomitance | #179 |
| thromboplastin time | #180 |
| referral bias | #180 |
| ventilation perfusion | #180 |
| patients deficiency | #180 |
| isth | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| testing patients | #182 |
| painkillers | #182 |
| acute episode | #182 |
| antithrombin | #182 |
| 2–4 | #183 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| 4150 | #184 |
| prognosis pulmonary | #184 |
| thromboinflammation | #184 |
| n110 | #184 |
| antithrombin iii atiii | #184 |
| risk bleeding | #184 |
| coagulation factors | #184 |
| subsequent diagnosis | #184 |
| pregnancy vte | #184 |
| treat analysis | #184 |
| incidental | #184 |
| vte age | #185 |
| deficient patients | #185 |
| live birth rate | #186 |
| brain natriuretic | #186 |
| hemostatic effects | #186 |
| anticoagulated | #186 |
| patients thromboprophylaxis | #186 |
| studies heparin | #186 |
| symptomatic | #186 |
| patients intensive units | #186 |
| risk composite | #187 |
| cutoff level | #187 |
| patients haemophilia | #187 |
| antifibrinolytic agents | #187 |
| safety apixaban | #187 |
| absolute rate | #188 |
| ratio inr | #188 |
| 926 | #188 |
| prevalence cancer | #188 |
| doacs vkas | #188 |
| humans international | #188 |
| spontaneous rupture | #188 |
| heparin administration | #189 |
| clinical validity | #189 |
| 64slice | #189 |
| riete | #189 |
| patients netherlands | #189 |
| blood loss patients | #189 |
| viia female | #189 |
| fibrinolysis | #189 |
| willebrand factor antigen | #189 |
| ischemic event | #190 |
| anticoagulant drugs | #190 |
| current views | #190 |
| thrombosis patients | #190 |
| ccus | #190 |
| attending physicians | #191 |
| gogh | #191 |
| acute thrombosis | #191 |
| score patients | #191 |
| venous outflow | #191 |
| 07 | #191 |
| 058 | #192 |
| 1495 | #192 |
| stroke systemic | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| 070 | #194 |
| heparin patients | #194 |
| prothrombin activation | #194 |
| anticoagulation | #194 |
| blood coagulation | #194 |
| target range | #195 |
| antagonist treatment | #195 |
| recurrent ischemic events | #195 |
| antixa levels | #195 |
| risk major | #195 |
| 65 months | #195 |
| 29 95 | #196 |
| coagulation status | #196 |
| abnormal test | #196 |
| complications cardiovascular | #196 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| ate | #198 |
| difference treatment | #198 |
| vii rfviia | #198 |
| sew2871 | #198 |
| patient diagnosis | #199 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| obese controls | #200 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients 12 months | #200 |
| thromboembolic disease | #201 |
| vte incidence | #201 |
| patients abnormal | #201 |
| validation sets | #201 |
| thrombin factor | #201 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| johnson | #202 |
| arterial thrombosis | #202 |
| heparin dose | #203 |
| invitees | #203 |
| worldwide survey | #203 |
| induced activation | #203 |
| symptomatic pad | #203 |
| antithrombotic agents | #204 |
| levonorgestrel | #204 |
| period time | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| extended thromboprophylaxis | #205 |
| low incidence | #205 |
| 0 95 | #205 |
| fgt | #206 |
| varese | #206 |
| data synthesis | #206 |
| venous ultrasonography | #206 |
| patients anticoagulant therapy | #206 |
| fviii | #207 |
| algorithms anticoagulants | #207 |
| imt patients | #207 |
| methods consecutive | #207 |
| 06 | #207 |
| systematic review studies | #207 |
| objectively | #207 |
| death female humans | #207 |
| desogestrel | #207 |
| platelet activation patients | #207 |
| cardiologist | #207 |
| bleeding compared | #208 |
| thrombocythaemia | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| antixa activity | #210 |
| tgt | #210 |
| hirudins | #210 |
| women frequency | #210 |
| systemic embolism patients | #211 |
| stocking | #211 |
| toxaemia | #211 |
| ioxaglate | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| heparitin sulfate | #213 |
| plasminogen activator activity | #213 |
| dabigatran dose | #214 |
| correct interpretation | #214 |
| topic practice | #214 |
| current developments | #215 |
| standard duration | #215 |
| studies rivaroxaban | #215 |
| thrombin inhibition | #215 |
| factors vte | #215 |
| duplex venous | #216 |
| warfarin stroke | #216 |
| community hospital | #216 |
| deamino | #216 |
| betatg | #216 |
| mildest | #217 |
| obviates | #217 |
| undergoing total | #217 |
| studies difference | #217 |
| diagnostic algorithm | #217 |
| npv 100 | #218 |
| plasminogen activator inhibitor | #218 |
| cstatistic | #218 |
| conclusive evidence | #218 |
| g20210a | #218 |
| patients cart | #219 |
| cancer | #219 |
| deamino arginine | #219 |
| 077 95 | #219 |
| data extraction | #220 |
| techniques female | #220 |
| viii female | #220 |
| hip replacement surgery | #220 |
| vii factor | #220 |
| heparin humans | #221 |
| preventive measures | #221 |
| postoperative vte | #221 |
| hmvec | #221 |
| healthy human subjects | #221 |
| proximally | #222 |
| vte events | #222 |
| apc resistance | #222 |
| pulmonologists | #223 |
| substantial proportion | #223 |
| 1541 | #223 |
| 1 january | #223 |
| engl | #223 |
| topic factor | #224 |
| protein pathway | #224 |
| thromboendarterectomy | #224 |
| subsequent cancer | #224 |
| org | #225 |
| thrombosis warfarin | #225 |
| balloon coronary anticoagulants | #225 |
| neoplasms prospective | #225 |
| kruskalwallis | #225 |
| extremity amputation | #226 |
| 16 95 | #226 |
| inr monitoring | #226 |
| vascular events patients | #226 |
| 0·67 | #226 |
| haemostasis | #227 |
| 35 ± | #227 |
| tests diagnosis | #227 |
| acute medical | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| dalteparin | #229 |
| cgp | #229 |
| scant | #229 |
| residual thrombus | #229 |
| 037 | #230 |
| advocated | #230 |
| severe preeclampsia | #231 |
| thiazoles | #231 |
| patients discontinuation | #231 |
| resource utilisation | #231 |
| urosepsis | #231 |
| ft4 | #231 |
| equinox | #231 |
| major orthopaedic surgery | #231 |
| 6 studies | #231 |
| habitual abortion | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| recurrence risk factors | #233 |
| dimer | #233 |
| endogenous thrombin potential | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| cancer prevalence | #233 |
| surgical embolectomy | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| doac | #235 |
| graduated compression | #235 |
| brain natriuretic peptide | #236 |
| venous thromboembolic events | #236 |
| humans meta | #236 |
| treatment continuation | #237 |
| myocardial infarction 95 | #237 |
| oral anticoagulants | #237 |
| patients vkas | #238 |
| 009 | #238 |
| predictive tests | #238 |
| 6500 | #238 |
| factor tnf | #239 |
| anticoagulants aspirin | #239 |
| factor viii fviii | #239 |
| rational approach | #239 |
| crossover study | #239 |
| patients initial treatment | #240 |
| arterial venous thrombosis | #240 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| aspirin heparin | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| patients intermittent claudication | #243 |
| pivotal trials | #243 |
| prothrombin fragment | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| children neonates | #246 |
| vte cases | #246 |
| casecontrol | #246 |
| thrombogenesis | #246 |
| antithrombotic | #247 |
| warfarin aged | #247 |
| 23 95 | #247 |
| lipoproteina levels | #247 |
| coronary anticoagulants | #248 |
| anti activity | #248 |
| treatment compared | #248 |
| committees | #248 |
| patients solid tumours | #248 |
| score risk | #249 |
| diagnostic models | #249 |
| multiple comorbidities | #249 |
| bleeding rates | #249 |
| protein risk | #250 |
| ioxaglic | #250 |
| fv leiden | #250 |
| ischemic strokes | #250 |
| 8595 | #251 |
| finalized | #251 |
| microthrombosis | #251 |
| patients contraindications | #251 |
| simplification | #252 |
| vkas doacs | #252 |
| somit | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| activation humans | #256 |
| medea | #256 |
| haul | #256 |
| activity assay | #257 |
| continuous intravenous | #257 |
| clinical utility | #257 |
| q24h | #257 |
| cost‐effectiveness | #257 |
| bleeding risk | #257 |
| patient subgroups | #258 |
| ctpa | #258 |
| fibrin degradation | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| heparin dosing | #261 |
| toxicosis | #261 |
| thrombus size | #261 |
| noncarriers | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| relation time | #269 |
| randomised cross | #269 |
| propeptide | #269 |
| versus aspirin | #269 |
| lysis time | #269 |
| malignancy patients | #269 |
| exclusion | #270 |
| single test | #270 |
| protein patients | #270 |
| discontinuing | #270 |
| hormonal replacement therapy | #271 |
| protein apc | #271 |
| thrombosis inflammation | #271 |
| orthopaedic patients | #271 |
| platelet serotonin | #271 |
| 3·0 | #271 |
| clopidogrel ticlopidine | #272 |
| bleeding patient | #272 |
| vte recurrence | #272 |
| groups levels | #272 |
| patients combination | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| prevalence pad | #274 |
| months 12 | #274 |
| cleavage sites | #274 |
| risk levels | #274 |
| performance score | #275 |
| parenteral nutrition patients | #275 |
| international normalized | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| normalized ratio | #278 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| aptt | #279 |
| rco | #279 |
| blood test | #279 |
| hospitalized medical | #280 |
| obviate | #280 |
| partial thromboplastin time | #280 |
| propositi | #280 |
| exclusion criteria | #280 |
| intracranial hemorrhage patients | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| departments | #284 |
| test characteristics | #284 |
| favor | #284 |
| noninferiority margin | #284 |
| animals anticoagulants | #284 |
| outpatient treatment | #284 |
| major orthopaedic | #285 |
| plasma bnp | #286 |
| patients apixaban | #286 |
| 2630 | #286 |
| gentamicin treatment | #286 |
| clinically | #287 |
| patients pancreatic cancer | #287 |
| disseminated intravascular | #287 |
| subdistribution | #287 |
| levels measured | #287 |
| premature atherosclerosis | #288 |
| 227 | #288 |
| oral combined | #288 |
| md patients | #288 |
| clot lysis | #289 |
| cvt patients | #289 |
| substantiation | #289 |
| vte women | #289 |
| vte rates | #289 |
| n59 | #290 |
| thrombin time | #290 |
| 0·50 | #290 |
| current clinical | #291 |
| 016 | #291 |
| carriers mutation | #291 |
| extracted data | #291 |
| oral contraceptives | #291 |
| activator inhibitor | #292 |
| 1603 | #292 |
| 2 studies | #292 |
| willebrand disease vwd | #292 |
| pentasaccharide | #293 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| patients dabigatran | #293 |
| adverse outcome patients | #293 |
| tissuetype plasminogen activator | #294 |
| patients rivaroxaban | #294 |
| cardiac troponin ctnt | #294 |
| lower extremities | #294 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| 1025 | #295 |
| coagulation factor viii | #296 |
| peripheral vascular | #296 |
| classified | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| thrombocytes | #298 |
| episode patients | #298 |
| specificity npv | #298 |
| recurrent miscarriage | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| toxemia | #302 |
| subclinical thyroid dysfunction | #302 |
| 155 patients | #302 |
| aged neoplasms | #302 |
| thromboglobulin | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| surgery day | #310 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| hematologic pregnancy | #310 |
| percentage points | #311 |
| antithrombins blood | #311 |
| clinical presentation | #311 |
| patients 100 | #311 |
| 105 patients | #311 |
| 598 | #312 |
| leg male | #312 |
| obesity risk factor | #313 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| diagnosis | #314 |
| postpartum haemorrhage | #315 |
| puerperium | #315 |
| heparin aspirin | #315 |
| funding | #315 |
| cardiologists | #315 |
| therapeutic dose | #316 |
| apixaban versus | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| deciding | #318 |
| 0·92 | #318 |
| safety outcomes | #319 |
| decision model | #319 |
| failure rates | #319 |
| patients pregnancy | #320 |
| influenza infections | #320 |
| 1731 | #320 |
| combined administration | #320 |
| bnp levels | #320 |
| catheter thrombosis | #320 |
| ventricular dysfunction patients | #321 |
| difference risk | #322 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| additional data | #322 |
| inrs | #324 |
| glaxosmithkline | #324 |
| peripheral arterial | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| mechanical heart valves | #326 |
| pulmonary embolus | #326 |
| 122 patients | #326 |
| blood coagulation factor | #326 |
| clinical | #327 |
| surgery trauma | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| 95 percent | #333 |
| n69 | #333 |
| analysis trials | #333 |
| embase databases | #333 |
| incidences | #334 |
| minor effects | #334 |
| complicate | #334 |
| 95 confidence limits | #334 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| total hip replacement | #337 |
| 035 | #337 |
| 065 | #337 |
| 2 points | #337 |
| recurrent | #337 |
| plethysmographic | #337 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| aged netherlands | #338 |
| coagulation abnormalities | #338 |
| placebo trials | #339 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| patients 12 | #340 |
| antithrombotic effects | #340 |
| 024 | #340 |
| 217 | #341 |
| activatable | #341 |
| coagulation markers | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| patients covid19 infection | #344 |
| pretest | #344 |
| antithrombotic strategies | #345 |
| vte prevention | #345 |
| splanchnic vein thrombosis | #345 |
| rfviia | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| 073 | #347 |
| 044 | #348 |
| cochrane central | #348 |
| bsf | #349 |
| chads2 | #349 |
| 2575 | #349 |
| tafia | #350 |
| randomized studies | #350 |
| brain predictive | #350 |
| trousseau | #350 |
| factor viii | #351 |
| 013 | #351 |
| versus warfarin | #351 |
| selection bias | #352 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| anticoagulants noacs | #352 |
| vein | #353 |
| 5075 | #353 |
| relative efficacy | #353 |
| oral anticoagulant therapy | #353 |
| 1590 | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| categorised | #357 |
| post hoc | #357 |
| intestinal microbiome | #357 |
| tests prospective studies | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| infrainguinal | #368 |
| patients 3 | #368 |
| time recurrence | #368 |
| thrombin inhibitor | #369 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 803 | #372 |
| 055 | #372 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| knee surgery | #373 |
| patients svt | #373 |
| clinical suspicion | #373 |
| human cytomegalovirus infection | #374 |
| patients scores | #374 |
| helical computed tomography | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| thromboembolic complications | #384 |
| 0·8 | #384 |
| reassessed | #384 |
| multivariate regression analysis | #384 |
| standardized questionnaire | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| conference proceedings | #386 |
| bleeding events | #386 |
| surrogate outcome | #386 |
| sensitivity npv | #387 |
| antithrombins | #387 |
| cumulative incidences | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| safety rivaroxaban | #389 |
| 880 | #389 |
| systemic embolism | #389 |
| referred | #389 |
| vitt | #390 |
| apixaban warfarin | #390 |
| tinzaparin | #390 |
| comparison patients | #391 |
| drug prescription | #391 |
| biosis | #391 |
| postop | #391 |
| abi | #391 |
| increased bleeding | #391 |
| patients chest | #392 |
| topic female humans | #392 |
| time presentation | #392 |
| kappa values | #393 |
| factors thrombosis | #393 |
| pulmonary emboli | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| background patients | #394 |
| 007 | #395 |
| bleeding event | #396 |
| 95 12 | #396 |
| popliteal | #396 |
| factors factor | #397 |
| embolic events | #397 |
| 665 | #397 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| risk score patients | #399 |
| patients risk | #400 |
| echography | #400 |
| heparin induced | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| increased risk vte | #403 |
| dabigatran | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| treatment patient | #406 |
| 075 | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| safety combination | #411 |
| 20 microg | #412 |
| transfusion patients | #412 |
| major risk factor | #412 |
| coagulation patients | #414 |
| euthyroidism | #414 |
| maastricht | #414 |
| aged odds | #415 |
| hypocortisolism | #415 |
| xii | #415 |
| deserve | #416 |
| pai1 levels | #416 |
| dose heparin | #416 |
| intravascular coagulation | #416 |
| data risk | #417 |
| 95 10 | #417 |
| comparable | #417 |
| 95 | #418 |
| carotid femoral | #418 |
| pretest probability | #418 |
| dermatan | #419 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| 2850 | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| cancer cohort | #426 |
| fii | #426 |
| randomised double | #426 |
| activated factor | #427 |
| consecutive | #427 |
| conferences | #428 |
| daily practice | #428 |
| plg | #428 |
| excessive bleeding | #428 |
| prolactin levels | #429 |
| idiopathic myelofibrosis | #429 |
| patients testing | #429 |
| daily clinical practice | #429 |
| undergoing elective | #429 |
| 1904 | #430 |
| heparinoids | #431 |
| rule | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| bolus injection | #437 |
| 059 | #437 |
| prostatic cancer | #439 |
| proven | #439 |
| composite point | #439 |
| dose adjustment | #439 |
| women compared | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| 074 | #442 |
| rate vte | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| patients parenteral nutrition | #449 |
| hellp | #449 |
| 58 | #449 |
| utrecht | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| aspirin risk | #453 |
| thrombin generation | #453 |
| fatal disease | #453 |
| 30 40 | #454 |
| placebo day | #454 |
| factor xii | #454 |
| portal blood | #454 |
| 12week | #455 |
| 026 | #455 |
| microthrombi | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| onwards | #457 |
| squibb | #457 |
| dicumarol | #457 |
| anti levels | #458 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| recommend | #460 |
| svt | #460 |
| plasma lipoprotein | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| curve biomarkers | #462 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| haemolysis | #463 |
| guidelines patients | #463 |
| patients values | #464 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| hemihepatectomy | #470 |
| test probability | #470 |
| 077 | #470 |
| roc analysis | #470 |
| inr patients | #470 |
| placebo recipients | #471 |
| case control study | #472 |
| prophylactic anticoagulation | #472 |
| hypercoagulability | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| heterozygote humans | #475 |
| plethysmograph | #475 |
| endotoxemia | #475 |
| patients heparin | #475 |
| 15 95 | #475 |
| intermittent pneumatic | #475 |
| atria | #477 |
| 08 | #479 |
| patients score | #479 |
| haemophiliacs | #479 |
| versus standard | #480 |
| hit patients | #481 |
| thrombosis cvt | #481 |
| acutely | #481 |
| advisory | #482 |
| postoperative blood | #482 |
| 1162 | #482 |
| transportability | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| diagnostic efficacy | #485 |
| patients hematologic malignancies | #485 |
| awaited | #486 |
| composite scores | #487 |
| secondary prophylaxis | #487 |
| travel | #488 |
| silent | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| new therapy | #493 |
| hemophilic | #493 |
| pan troglodytes | #493 |
| p00007 | #493 |
| treatment period | #493 |
| residual risk | #493 |
| vcf | #494 |
| activated protein | #495 |
| replacement hip arthroplasty | #496 |
| favour | #496 |
| dose oral | #496 |
| heterozygote | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| willebrand disease | #498 |
| risk factors stroke | #498 |
| blockages | #498 |
| discriminative ability | #498 |
| hip knee | #501 |
| ptp | #502 |
| nri | #502 |
| subcategories | #503 |
| ft4 tsh | #503 |
| deficiencies | #503 |
| rapid decrease | #504 |
| patients referred | #505 |
| 1107 | #505 |
| complications pulmonary | #505 |
| nondiagnostic | #505 |
| net clinical | #506 |
| 310 | #506 |
| day surgery | #507 |
| oftentimes | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| coagulation tests | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| aminocaproates | #509 |
| contraceptives | #509 |
| thrombosis animals | #510 |
| angiography patients | #510 |
| new oral anticoagulants | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| epiphenomenon | #512 |
| 019 | #512 |
| serial | #513 |
| interim analysis | #514 |
| highintensity | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| protein antithrombin | #518 |
| sensitivity diagnosis | #518 |
| thrombophilia thrombosis | #518 |
| thrombotic diseases | #518 |
| bleeding outcomes | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| 8090 | #521 |
| duration intensity | #521 |
| 1599 | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cindices | #528 |
| cancer age | #528 |
| convincing | #529 |
| 051 | #529 |
| 378 | #529 |
| 923 | #529 |
| fatal | #530 |
| health female | #530 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| humans postoperative | #531 |
| betaalanine | #531 |
| intensive units icu | #532 |
| ≥50 years | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| patients idiopathic | #538 |
| 449 | #538 |
| humans neoplasms | #538 |
| comprehensive search | #539 |
| cbo | #539 |
| concise | #539 |
| ddavp | #539 |
| diagnosis acute | #540 |
| clinical review | #540 |
| diagnostic accuracy studies | #540 |
| thrombotic risk | #543 |
| 234 | #543 |
| bleeding episodes | #543 |
| vascular obstruction | #543 |
| conventional treatment | #543 |
| patients eligible | #543 |
| jak2 mutation | #544 |
| 00 | #544 |
| pad abi | #544 |
| coagulative | #544 |
| perc | #545 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| v617f | #545 |
| association statin | #546 |
| screening strategies | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| 95 difference | #549 |
| overt | #549 |
| adequate | #549 |
| percent patients | #550 |
| 1103 | #550 |
| conduction anesthesia | #550 |
| cancer type | #550 |
| reviewers | #550 |
| platelet inhibitors | #550 |
| studies sensitivity | #552 |
| 500 patients | #552 |
| careful | #552 |
| amsterdam | #552 |
| day patients | #552 |
| management bleeding | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| factor vii | #558 |
| 66 patients | #558 |
| vivo treatment | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| patients transfusion | #563 |
| female humans tests | #563 |
| risk development | #563 |
| board directors | #563 |
| appears | #564 |
| anamnesis | #564 |
| hip replacement | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| solid tumours | #566 |
| withholding | #566 |
| cardiac troponins | #566 |
| roc curves | #568 |
| n46 | #568 |
| patients 2 years | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| revascularization procedures | #574 |
| cutoff point | #574 |
| menstrual bleeding | #574 |
| major bleedings | #575 |
| subcutaneously | #575 |
| women proportion | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| thiophenes | #579 |
| pharma | #579 |
| endotoxin | #579 |
| 99 | #580 |
| diagnostic tools | #580 |
| notice | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| 094 | #585 |
| coagulation disorders | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| healthy human | #590 |
| thrombophilias | #590 |
| reversal agents | #590 |
| malignancy | #590 |
| beta alanine | #590 |
| doppler ultrasound | #592 |
| massive pulmonary | #592 |
| conventional management | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| severe bleeding | #597 |
| major hemorrhage | #597 |
| ldf | #597 |
| patency rates | #597 |
| replacement knee | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| clinical characteristics patients | #604 |
| events occurred | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| initial increase | #607 |
| patients antibodies | #607 |
| 0·3 | #607 |
| activated coagulation | #607 |
| treatment acute | #608 |
| tissue factor | #609 |
| arbitrage | #609 |
| pfizer | #609 |
| benefit risk | #610 |
| airline | #610 |
| patients death | #610 |
| 100 years | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| patients bariatric surgery | #615 |
| leg | #615 |
| reluctant | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| stroke atrial fibrillation | #618 |
| occurred | #618 |
| 467 | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| sgs | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| women risk factors | #628 |
| 5000 | #628 |
| 66 | #628 |
| warfarin risk | #628 |
| human subjects | #629 |
| referral patients | #629 |
| diagnostic algorithms | #629 |
| physical training | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| proceedings | #641 |
| study quality | #641 |
| predictive performance | #642 |
| 3050 | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| necessitating | #648 |
| studies efficacy | #648 |
| statin treatment | #648 |
| 036 | #651 |
| thrombolysis patients | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| bleeding death | #659 |
| coronary stent implantation | #659 |
| 69 | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| provoked | #664 |
| long term treatment | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| patients completed | #667 |
| guideline adherence | #667 |
| onethird | #667 |
| presence patients | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| clotting factors | #675 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| myocardial infarctions | #693 |
| graduated | #693 |
| activator pa | #693 |
| intracranial bleeding | #694 |
| precise mechanisms | #694 |
| administer | #694 |
| composite outcome | #694 |
| 1718 | #695 |
| moyamoya | #696 |
| combined oral contraceptives | #696 |
| stroke prevention patients | #696 |
| ratio male | #698 |
| participant data | #698 |
| difference 95 | #698 |
| episode | #700 |
| compression devices | #700 |
| therapeutic management | #702 |
| prothrombin gene | #702 |
| diagnostic errors | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| 048 | #712 |
| gynaecology | #712 |
| medical patients | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| adequately | #717 |
| cancer groups | #717 |
| 10 30 | #718 |
| solid cancer | #718 |
| falsely | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| clinical judgment | #721 |
| accp | #721 |
| pyrazoles pyridines | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| 59 patients | #727 |
| gentamicins | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| clinical prediction rule | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| 040 | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| molecular weight | #744 |
| betathromboglobulin | #744 |
| 285 | #746 |
| antithrombin activity | #746 |
| etp | #746 |
| patients 50 years | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| 95 risk factors | #756 |
| pneumatic compression | #756 |
| hf risk | #756 |
| answer | #756 |
| 95 combination | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| risk pregnancy | #767 |
| 689 | #767 |
| aspirin clopidogrel | #767 |
| 732 | #768 |
| method drug | #769 |
| groups patients | #770 |
| relevant | #770 |
| 566 | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| patients 65 years | #778 |
| study groups | #778 |
| dose intravenous | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| plasmin generation | #780 |
| 066 | #780 |
| patients hyperthyroidism | #780 |
| thromboembolism prophylaxis | #780 |
| age ≥ | #782 |
| onefifth | #785 |
| factor ixa | #785 |
| abnormalities patients | #786 |
| cteph | #787 |
| general practitioners | #787 |
| 100 personyears | #787 |
| topic disease models | #787 |
| polypharmacy | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| 047 | #795 |
| inactivators | #795 |
| risk factors risk | #795 |
| patient years | #796 |
| patency | #796 |
| eligible | #797 |
| studies prevalence | #797 |
| netherlands | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| patients lower | #799 |
| estrogen therapy | #799 |
| theme | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| factor vwf | #816 |
| flights | #816 |
| 0·4 | #818 |
| health predictive | #820 |
| vehicle control | #820 |
| irrespective | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| myers | #833 |
| 93 | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| patients diagnosis | #850 |
| caesarean | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| tasman | #873 |
| favoring | #873 |
| imaging reproducibility | #874 |
| thromboembolic pulmonary | #874 |
| targeted inhibition | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| anticoagulants atrial | #879 |
| 57 | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| domiciliary | #894 |
| 084 | #894 |
| male mexico | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| factor activity | #908 |
| 064 | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| standard patients | #920 |
| randomeffects model | #920 |
| antagonist oral | #920 |
| optimal dose | #921 |
| loss patients | #921 |
| ultrasound examination | #921 |
| practise | #923 |
| estimate male | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| diagnostic | #948 |
| extensive disease | #948 |
| knee replacement | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| cancer humans | #956 |
| dic | #956 |
| network metaanalysis | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| efficacy | #958 |
| day1 | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| risk allcause mortality | #973 |
| antiplatelet | #973 |
| hoc | #973 |
| prevalence characteristics | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 50 100 | #980 |
| 071 | #980 |
| onset aged aged | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| lower extremity | #1000 |
| thromboembolic risk | #1000 |
| justification | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| interleukin 6 | #1005 |
| extended | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| risk hemorrhage | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| birth rate | #1060 |
| coagulant | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| 101 | #1066 |
| live birth | #1066 |
| 00008 | #1066 |
| cut | #1067 |
| lysosphingolipid | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| thorax | #1074 |
| laboratory diagnosis | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| idarucizumab | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| 445 | #1126 |
| new perspectives | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| refusal | #1150 |
| roc curve | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| viii | #1164 |
| stable angina | #1164 |
| intermittent | #1164 |
| safety concerns | #1164 |
| hyperhomocysteinemia | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| perioperative bleeding | #1172 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| glucocorticoid treatment | #1172 |
| practice guideline | #1173 |
| occlusive diseases | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| hospitalized patients | #1182 |
| unaware | #1182 |
| patients obesity | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| international society | #1199 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| 015 | #1204 |
| categorized | #1204 |
| quantitative trait locus | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| warranted | #1221 |
| patient treatment | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| ml1 | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| search strategy | #1257 |
| extensive | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| entity | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| 75 years | #1281 |
| routine screening | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| perfusion defects | #1295 |
| scan | #1295 |
| janssen | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| pf4 | #1303 |
| 61 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| risk difference | #1312 |
| cyproterone | #1312 |
| 1st | #1312 |
| apoa | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| 0·7 | #1314 |
| current strategies | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| beneficial | #1329 |
| low moderate | #1330 |
| thyroid disorders | #1330 |
| plasminogen activators | #1330 |
| 6 months patients | #1331 |
| 77 | #1331 |
| coagulation cascade | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| 15 patients | #1359 |
| experimental model | #1359 |
| vwf | #1363 |
| limb salvage | #1363 |
| arsenal | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| dl1 | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| 82 | #1402 |
| antisense oligonucleotide | #1402 |
| equipoise | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 6 weeks | #1419 |
| 7 weeks | #1419 |
| 3 6 | #1419 |
| thrombotic complications | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| 061 | #1424 |
| ≥55 | #1424 |
| daily | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| imaging radiopharmaceuticals | #1439 |
| 096 | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| weight bmi | #1446 |
| drug levels | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| aged blood | #1455 |
| platelet factor | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| 0·9 | #1468 |
| avoided | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| patients 10 | #1520 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| deficient | #1568 |
| hyperlipoproteinemia type | #1568 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| activation markers | #1586 |
| cocs | #1586 |
| thyroid dysfunction | #1586 |
| study entry | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| tests reproducibility | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| cvd patients | #1619 |
| female hemostasis | #1619 |
| imaging tomography | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| incidentally | #1632 |
| pa patients | #1632 |
| venous disease | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| dorsiflexion | #1651 |
| 997 | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| diagnostic evaluation | #1721 |
| female femoral | #1721 |
| mb | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| 691 | #1745 |
| patients ventricular | #1745 |
| table | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| apc | #1749 |
| turp | #1749 |
| homozygosity | #1750 |
| replacement | #1750 |
| pselectin | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| treatment recommendations | #1760 |
| audiometry | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| arteriosclerosis | #1770 |
| hemorrhage | #1770 |
| allcause death | #1774 |
| 2 6 | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| 95 specificity | #1812 |
| tumor necrosis | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| preference | #1825 |
| screening middle | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| definite | #1837 |
| compressibility | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| diagnostic techniques | #1892 |
| shrs | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| tnf | #1901 |
| extremity | #1901 |
| diagnostic testing | #1901 |
| clt | #1905 |
| induced thrombocytopenia | #1906 |
| hazard ratio | #1906 |
| plaster | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| 48 hours | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| specificity ultrasonography | #1981 |
| 771 | #1981 |
| hyperaldosteronism | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| 018 | #1992 |
| prospero | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| 097 | #2033 |
| patients lung | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| 188 | #2074 |
| mcnemar | #2074 |
| national institute | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| reference range | #2099 |
| preformed | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| 59 | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| substantial | #2109 |
| 031 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| coronary stent | #2122 |
| acl reconstruction | #2125 |
| original | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| 2 × | #2185 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| neutrophil elastase | #2212 |
| diagnosis differential | #2212 |
| doubled | #2213 |
| 364 | #2219 |
| pao2 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| protein | #2413 |
| periodicals | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| 0048 | #2430 |
| 002 | #2430 |
| coagulants | #2430 |
| legs | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| ptca | #2434 |
| prolonging | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 164 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| hours | #2560 |
| haematology | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| humans logistic | #2574 |
| 73 | #2574 |
| kits | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| efficacious | #2585 |
| 591 | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| trials rcts | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| benzimidazoles | #2662 |
| c677 | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| outcome ultrasonography | #2683 |
| 516 | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| aso | #2691 |
| 594 | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| 143 | #2768 |
| management acute | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| 402 | #2802 |
| consecutive series | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| contacting | #2835 |
| recurrence rate | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| 21 | #2897 |
| systematic review metaanalysis | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| benchmark | #3110 |
| trimester | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| lifelong | #3122 |
| wallis | #3122 |
| oac | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| suggested | #3219 |
| cancer types | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| concluded | #3379 |
| 301 | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| 553 | #3403 |
| tunica | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| hypothesised | #3420 |
| study risk | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| pregnancy complications | #3472 |
| patients receive | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| cancer metastasis | #3485 |
| antiphospholipid | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| homozygote | #3642 |
| undergo | #3642 |
| bypass surgery | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| fibrillation | #3651 |
| interindividual variability | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| inhibitors humans | #3725 |
| pharmacodynamics | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| subgroup analyses | #3762 |
| 8 patients | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| interpretable | #3778 |
| 517 | #3778 |
| 483 | #3782 |
| total knee arthroplasty | #3789 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| compelling | #3804 |
| vessel wall | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| 351 | #3890 |
| difference | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| behalf | #3971 |
| austrian | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| 986 | #3982 |
| pregnancy | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| natriuretic peptide | #4089 |
| oligosaccharides | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| indications | #4099 |
| cutoff | #4099 |
| activation | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| withdrawn | #4137 |
| 008 | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| bowel diseases | #4407 |
| 71 | #4407 |
| general | #4407 |
| negative | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| immunoassays | #4419 |
| dose aspirin | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| 204 | #4596 |
| simplified | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| habitual | #4658 |
| 003 | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| 171 | #4670 |
| myelofibrosis | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| fh | #4680 |
| day | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| tests prognosis | #4906 |
| preparations | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| 389 | #5006 |
| references | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| screening test | #5040 |
| 156 | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| regarded | #5089 |
| evaluable | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| male | #5363 |
| schedule drug | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| established | #5563 |
| receptor1 | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| atrial | #5852 |
| true | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| aged platelet | #5928 |
| 22 patients | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| mortality morbidity | #6228 |
| terminated | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| 318 | #6524 |
| washout | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| genetic testing | #6641 |
| pancreatic neoplasms | #6641 |
| complications | #6650 |
| individual | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| intensity | #6976 |
| 246 | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| sensitivity analysis | #7290 |
| modest | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| p0001 | #7356 |
| myocardial infarction | #7356 |
| standardised | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| comorbid | #7578 |
| cinahl | #7578 |
| 191 | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| medical conditions | #7705 |
| 18 | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| hormone replacement | #7828 |
| label | #7828 |
| 31 patients | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| preventable | #8051 |
| medical | #8051 |
| 600 | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lists | #8250 |
| lowest | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| practical | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| micrograms | #8914 |
| planned | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| patients placebo | #9002 |
| options | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| clinical events | #9007 |
| societies medical | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| mps | #9080 |
| diagnose | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| nmol | #9828 |
| coa reductase | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| priority | #10461 |
| patients age | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| style | #10491 |
| 1991 | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| summarizes | #11062 |
| attained | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| outflow | #11542 |
| multicenter study | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| vascular | #13708 |
| competence | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| renal insufficiency | #14637 |
| statistics | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| acute phase | #17288 |
| largest | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
レポートを実行します | |
のための重要な人々 Pulmonary Embolism
世界のトップコル
Harry Roger Büller:専門家の影響
その概念Harry Roger Büller直接的な影響があります:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOLインパクト
他の著者の仕事に関連する概念for which Harry Roger Büller 影響力があります:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
これはあなたのプロフィールですか？ あなたのプロフィールを主張します URLをコピーします プロフィールへのリンクを埋め込みます |